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Postoperative pain is inadequately 
treated and potential origin of 
persisting pain. The present study 
investigated acute and persisting 
pain after CABG surgery as well as 
propacetamol and S(+)-ketamine in 
pain therapy. Remifentanil´s effect on 
postoperative pain was also explored. 
Postoperative pain was moderate 
at rest, whereas dynamic pain was 
severe after surgery. One year after 
the operation persisting pain was 
common, although seldom severe. 
The efficacy of propacetamol and S(+)-
ketamine as analgesics after surgery 
was weak. Remifentanil did not 
increase pain postoperatively.
 
 
 
PASI LAHTINEN 
 
 
 
Pain after Coronary Artery Bypass  
Grafting Surgery 
 
 
Clinical Studies of Acute and Persistent Postoperative Pain 
 
 
 
 
 
 
 
To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland for 
public examination in the Kuopio University Canthia Auditorium 3, Kuopio, on Friday, October 12th  
2012, at 12 noon 
 
 
Publications of the University of Eastern Finland 
 Dissertations in Health Sciences  
Number 126 
 
 
Department of Anesthesiology, Kuopio University Hospital and Institute of Clinical Medicine, 
 School of Medicine, Faculty of Health Sciences, University of Eastern Finland 
Kuopio  
2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kopijyvä Oy 
Kuopio, 2012 
 
Series Editors:  
Professor Veli-Matti Kosma, M.D., Ph.D. 
Institute of Clinical Medicine, Pathology 
Faculty of Health Sciences 
 
Professor Hannele Turunen, Ph.D. 
Department of Nursing Science 
Faculty of Health Sciences 
 
Professor Olli Gröhn, Ph.D. 
A.I. Virtanen Institute for Molecular Sciences 
Faculty of Health Sciences 
 
Distributor:  
University of Eastern Finland 
Kuopio Campus Library 
P.O.Box 1627 
FI-70211 Kuopio, Finland 
http://www.uef.fi/kirjasto 
 
ISBN (print): 978-952-61-0872-8 
ISBN (pdf): 978-952-61-0873-5 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-570
  
III
Author’s address: Department of Anesthesiology 
Kuopio University Hospital 
P.O. Box 1777 
70211 
KUOPIO 
FINLAND 
 
Supervisors: Professor Hannu Kokki, MD, Ph.D. 
Department of Anesthesiology 
Kuopio University Hospital 
University of Eastern Finland 
KUOPIO 
FINLAND 
 
Professor Markku Hynynen, MD, Ph.D. 
Department of Anesthesiology 
Jorvi Hospital/Helsinki University Hospital 
Espoo 
University of Helsinki 
HELSINKI 
FINLAND 
 
Reviewers: Professor Andrew R. Wolf, MD 
Pediatric Intensive Care Unit 
Bristol Children's Hospital 
BRISTOL 
UNITED KINGDOM 
 
Professor Jouko Jalonen, MD, Ph.D 
Department of Anesthesiology and Intensive Care 
Turku University Hospital 
University of Turku 
TURKU 
                FINLAND  
 
 
Opponent: Professor Eija Kalso, MD, Ph.D. 
Pain Clinic, Department of Anesthesiology and Intensive Care 
Helsinki University Hospital 
University of Helsinki 
HELSINKI 
FINLAND 
  
 
 
IV
  
V
 
Lahtinen, Pasi 
Pain after Coronary Artery Bypass Grafting Surgery. Clinical studies of acute and persistent postoperative 
pain, 57 p. 
University of Eastern Finland, Faculty of Health Sciences, 2012 
Publications of the University of Eastern Finland. Dissertations in Health Sciences Number 126. 2012. 57 p. 
 
ISBN (print): 978-952-61-0872-8 
ISBN (pdf): 978-952-61-0873-5 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
ABSTRACT 
 
Pain after cardiac surgery has long been neglected and considered insignificant. 
Postoperative pain has only recently been recognized as an important problem and a 
potential origin of persistent pain and long-term suffering. Changing surgical and 
anesthesia practices have placed new demands on postoperative care after cardiac surgery.  
There are few prospective studies of acute and persisting pain after cardiac surgery. 
Although acute postoperative pain has been mild in retrospective studies, persistent long-
term pain has high prevalence: 21% to 56%. However, in most studies the time interval 
between surgery and completion of the postoperative questionnaire has been long, which 
might have affected the data gathered. The present study was conducted to investigate 
patients’ expectations and experiences of acute and persisting postoperative pain after 
cardiac surgery. The questionnaires were performed preoperatively; on the fifth 
postoperative day; and at 1, 3, 6, and 12 months after surgery. The second aim was to study 
the efficacy and feasibility of the opioid adjuvants propacetamol and ketamine in acute 
pain therapy after cardiac surgery. We also explored whether remifentanil infusion during 
coronary artery bypass grafting (CABG) surgery will increase pain and opioid 
requirements postoperatively. 
Patients experienced more postoperative pain at rest than they had expected 
preoperatively. The worst reported acute postoperative pain was severe in 49% of patients 
at rest, in 79% during coughing, and in 62% on movement. One year after the operation, 
14% of patients reported mild persisting post-sternotomy pain at rest, 1% experienced 
moderate pain, and 3% experienced severe pain. Patients with moderate to severe acute 
postoperative pain reported chronic post-sternotomy pain more frequently than patients 
with only mild postoperative pain. 
Propacetamol had no opioid-sparing effect, nor did it enhance analgesia after CABG 
surgery. However, in post hoc analysis, oxycodone requirement was reduced 
approximately 19% in the propacetamol group compared with the placebo group during 
the first 24 h after surgery. 
S(+)-ketamine had an opioid-sparing effect (1 %) after CABG surgery. However, pain 
scores or adverse events were not reduced compared with the placebo group. Three-h 
remifentanil infusion (0.3µg/kg/min) did not increase postoperative pain or postoperative 
opioid consumption. 
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TIIVISTELMÄ  
 
Tutkimusten mukaan leikkauksen jälkeisen kivun hoito on usein riittämätöntä. Erityisesti 
sydänleikkausten jälkeistä kipua on pitkään vähätelty ja kivun vaikutuksia leikkauksen 
jälkeiseen toipumiseen on pidetty merkityksettömänä. 
Sydänleikkauspotilaiden kivunhoito on perinteisesti toteutettu laskimonsisäisesti tai 
lihakseen annetuilla opioideilla. Opioidilääkityksen haittana on hengitystä lamaava 
vaikutus, sedaatio sekä oksentelun, pahoinvoinnin, suolilaman, ja virtsaretention 
lisääntyminen. Tutkimuksia kivunhoidosta sydänkirurgian jälkeen on vähän ja 
potilasmäärät näissä tutkimuksissa ovat pieniä. Taaksepäin katsovissa tutkimuksissa 
akuutti leikkauksen jälkeinen kipu on ollut lievää, mutta pitkäaikaista kipua on esiintynyt 
huomattavan paljon 21- 56 %:n. Tutkimukset on kuitenkin tehty usein pitkän ajan kuluttua 
leikkauksesta, mikä voi vaikuttaa tulosten luotettavuuteen. 
Tässä tutkimuksessa selvitettiin potilaiden odotuksia ja kokemuksia akuutista ja 
pitkäaikaisesta sydänleikkauksen jälkeisestä kivusta leikkausta edeltävänä päivänä, 
viidentenä leikkauksen jälkeisenä päivänä, 1, 3, 6 ja 12 kuukautta leikkauksen jälkeen. 
Lisäksi selvitettiin propasetamolin ja ketamiinin tehoa, soveltuvuutta ja turvallisuutta 
kipulääkkeiksi sydänleikkauksen jälkeen sekä remifentaniilin vaikutusta sydänleikkauksen 
jälkeiseen kipuun ja kipulääkkeen tarpeeseen. 
Potilaiden kokema leikkauksen jälkeinen kipu oli kovempaa levossa kuin he odottivat 
ennen leikkausta tehdyssä kyselyssä. Pahin leikkauksen jälkeinen kipu oli kovaa 49%:lla 
potilaista levossa, 79%:lla yskiessä ja liikkuessa 62%:lla. Vuoden kuluttua leikkauksen 
jälkeen kipu oli lievää 14%:lla potilaista levossa, 1%:lla potilaista kipu oli kohtalaisen kovaa 
ja 3%:lla kovaa. Potilailla, joilla oli kohtalaisen kovaa tai kovaa leikkauksen jälkeistä kipua 
heti leikkauksen jälkeen, oli useammin myös pitkäaikaista leikkauksen jälkeistä kipua vuosi 
leikkauksen jälkeen. 
Propasetamoli ei vähentänyt leikkauksen jälkeistä oksikodonin kulutusta eikä kipua 
sepelvaltimoiden ohitusleikkauksen jälkeen. Propasetamoli kuitenkin vähensi oksikodonin 
tarvetta ensimmäisen vuorokauden aikana 19%:lla lumelääkkeeseen verrattuna.  
S(+)-ketamiinilla oli leikkauksen jälkeistä oksikodonia vähentävä vaikutus, (17% 
pienempi lumelääkkeeseen verrattuna), vaikkakaan leikkauksen jälkeinen kipu tai 
opioidien aiheuttamat haittavaikutukset eivät vähentyneet.  
Remifentaniili ei lisännyt leikkauksen jälkeisen oksikodonin tarvetta eikä leikkauksen 
jälkeistä kipua leikkauksen aikana jatkuvana infuusiona (0.3 µg/kg/min) annosteltuna.  
 
 
Yleinen Suomalainen asiasanasto: kipu; kivunhoito; sydänkirurgia  
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1 Introduction 
Postoperative pain remains a challenge despite many new techniques, modern 
pharmaceutical analgesic preparations, and established pain services. Today one-third of 
postoperative patients experience moderate to severe pain (Dolin et al. 2002). Inadequate 
postoperative analgesia is associated with several adverse outcomes, i.e. tachycardia, 
increased oxygen consumption, hypercoagulability, pulmonary complications, 
psychological consequencies, etc (Liu et al. 2007). 
Traditionally, anesthesia in cardiac surgery has been managed using high doses of 
intravenous (i.v.) opioids during surgery, and postoperative pain has been mostly 
alleviated by intramuscular (i.m.) or i.v. opioids. Because of generous opioid delivery 
during surgery, the intensity of postoperative pain was assessed as mild and not worth 
much consideration (Schwann and Chaney. 2003). However, using high-dose opioid 
anesthesia necessitated long ventilator therapy postoperatively. Therefore, it has been 
replaced with fast-track anesthesia techniques involving balanced anesthesia with low-dose 
or short-acting analgesics. This fast-track regimen of surgical care has enhanced recovery, 
leading to shortened hospital stays with decreased morbidity, and is also widely and 
increasingly being adopted in cardiovascular surgery. The concept of fast-track cardiac 
surgery requires more intensive and sophisticated postoperative analgesic techniques than 
merely on-demand i.m. opioid injections. Multimodal analgesia, including local and 
epidural anesthesia, non-opioid systemic analgesics, and sophisticated opioid delivery 
techniques with patient-controlled analgesia (PCA) devices, have been shown to offer 
effective pain therapy in general surgery. In contrast to general surgery, epidural analgesia 
is potentially hazardous in cardiac surgery patients because of systemic anticoagulation 
with full heparinization and the risk of epidural hematoma (Svircevic et al. 2011). Likewise, 
non-steroidal anti-inflammatory drugs (NSAIDs), which are used widely as analgesic 
adjuvants in general surgery, are potentially hazardous in cardiac surgery owing to their 
potentially deleterious effects on renal, hemostatic, and cardiovascular homeostasis, and 
are thus seldom used after cardiac operations (Nussmeier et al. 2005). Therefore, it is 
necessary to identify and evaluate the efficiency and safety of different analgesic adjuncts to 
opioid-based pain therapy after cardiac surgery. 
Remifentanil is a short-acting opioid that is widely used in fast-track cardiac anesthesia. 
Although a potent analgesic during surgery, remifentanil has been suggested to induce 
opioid tolerance (exaggerated opioid consumption) and hyperalgesia (increased pain 
intensity) after the operation. Remifentanil’s potential to induce opioid tolerance after 
cardiac surgery remains to be clarified. 
Intensive postoperative pain may lead to permanent changes in the nervous system, 
predisposing patients to persistent postoperative pain that can last months or years after 
surgery. Little is known about persistent pain after cardiac surgery. The aim of the current 
studies was threefold. First, we endeavored to examine the incidence and intensity of pain, 
as well as patients’ preoperative expectations and postoperative experiences of pain after 
cardiac surgery in a prospective cohort. The second aim was to investigate whether 
perioperative short-acting opioid remifentanil induces opioid tolerance postoperatively. 
The third aim was to test the efficacy of propacetamol and ketamine as analgesic adjuncts to 
opioid-based pain therapy after cardiac surgery. 
  
 
  
 
 
2
 
2 Review of the Literature  
2.1 IMPLICATIONS OF POSTOPERATIVE PAIN 
Severe uncontrolled pain can hinder or delay early recovery and have a long-lasting effect 
on quality of life (QOL). 
Tissue trauma and elective surgery each elicit a stress response that may result in 
multiple adverse outcomes regarding bodily homeostasis. Through afferent neural stimuli 
and activation of the autonomic nervous system and spinal reflexes, pain per se may be an 
important trigger of surgical stress response. Uninhibited stress response and inadequately 
treated pain may lead to adverse hemodynamic responses (tachycardia, dysrhythmias, 
hypertension, vasoconstriction, and increased cardiac oxygen demand); metabolic 
(increased catabolism), immunologic (immunosuppression) and pulmonary complications 
(atelectasis, pneumonia); coagulation disorders (hypercoagulability, platelet activation); 
and increased ICU or hospital stay (Wu et al. 2000). Inadequate pain control is also one of 
the most important reasons for unanticipated hospital admissions after ambulatory surgery 
(Mattila et al. 2009). Severe postoperative pain has been shown to decrease QOL during the 
immediate postoperative period (within 2 weeks of surgery) (Wu et al. 2003) and patients 
with chronic pain reported lower health-related QOL compared with patients without 
chronic pain, measured using the Short-Form Health Survey (SF-36), at 12 months (Gjeilo et 
al. 2007) and more than 2 years (Taillefer et al. 2006) after cardiac surgery. 
Despite modern analgesia methods, pain after surgery may persist well after wound 
healing has taken place; in many patients, chronic pain persists for months or even years 
after surgery. According to recent reports, an alarmingly high number of patients develop 
chronic pain states after elective surgery (Gärtner et al. 2009 and Grosen et al. 2012). After 
coronary artery bypass (CABG) surgery, the estimated incidence of chronic pain is 30-50% 
and the incidence of severe, disabling pain is 5-10% (Bruce et al. 2003, Eisenberg et al. 2001, 
Gjeilo et al. 2010, Jensen and Andersen. 2004, Kalso et al. 1992, Meyerson et al. 2001). This is 
of concern because chronic pain is independently related to low self-rated health in the 
Finnish general population, and self-rated health was an independent predictor of 
mortality (Mäntyselka et al. 2003). 
 
2.2 BENEFITS OF ACUTE PAIN THERAPY 
Increasing attention has been focused on patients’ right to receive adequate pain relief, and 
“failure to treat pain is considered poor medicine, unethical practice and an abrogation of 
fundamental human right” (Brennan et al. 2007). The International Association for the 
Study of Pain (IASP) has stated in the Declaration of Montreal (International Pain Summit 
Of The International Association For The Study Of,Pain. 2011), Article 3:” The right of all 
people in pain to have access to appropriate assessment and treatment of the pain by 
adequately trained health care professionals.” 
Post-procedural pain is the most important concern in patient’s evaluation of 
anticipated postoperative problems (Elsass et al. 1987). Sufficient postoperative analgesia 
prevents unnecessary patient discomfort and suffering. Few studies investigating the 
benefits of postoperative analgesia have focused on mortality or major morbidity. In non-
cardiac surgery, two earlier studies suggested that intensive postoperative pain therapy 
may improve outcome (Park et al. 2001, Yeager et al. 1987). There is also evidence for 
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improved outcome in cardiac surgery with intensive postoperative analgesia (Mangano et 
al. 1992). Mangano et al. randomly assigned 106 adult CABG patients to receive either 
small, intermittent i.v. boluses of morphine or continuous sufentanil infusion during 18 
postoperative hours. The patients that received continuous sufentanil infusion experienced 
fewer myocardial ischemic episodes (as diagnosed by ECG) postoperatively. The authors 
suggested that the observed effect was based on suppressed sympathetic nervous system 
activation. Another study of 45 neonates undergoing cardiac surgery found that more 
intensive analgesia for the first 24 postoperative hours (i.e., continuous infusion of 
sufentanil or fentanyl compared with intermittent morphine boluses) reduced perioperative 
stress response and decreased morbidity and mortality compared with intermittent boluses 
of morphine (Anand and Hickey. 1992). However, high-dose i.v. opioids are associated 
with prolonged ventilatory depression postoperatively, and are no longer considered 
appropriate. Recently, spinal anesthesia and short-acting opioids were also shown to 
effectively suppress the stress response in pediatric cardiac surgery (Wolf. 2012, Weale et al. 
2004). 
Given that postoperative mortality is presently very low, it would be difficult to 
demonstrate a mortality benefit in single studies concentrating on pain therapy alone. In 
the United States, a random 5% sample of Medicare insurance claims (1997-2001) presented 
a postoperative 30-day mortality rate of 2.5% after various surgical operations (Wu et al. 
2006). Even higher-risk operations like CABG surgery are associated with a low mortality 
rate. An observational analysis of 693,637 patients in 2008 reported a mortality rate of 2.8% 
(Mehta et al. 2008). Surgical and anesthesia techniques have continued to evolve since these 
studies, and mortality rates are proposed to be even smaller today. Because of low 
postoperative mortality rates, most studies conducted to find a benefit of postoperative 
analgesia on mortality have lacked adequate sample size. Therefore, many meta-analyses 
and systematic reviews have been completed (Svircevic et al. 2011b, Wu et al. 2005, Beattie 
et al. 2003, Liu and Wu. 2007, Meylan et al. 2009). 
There is some evidence that effective postoperative analgesia in the form of i.v. PCA 
(opioids) or thoracic epidural local anesthetics (TEA) decreases pulmonary complications 
and might reduce postoperative cardiac complications (myocardial infarction, cardiac 
arrhythmias) (Beattie et al. 2001, Beattie et al. 2003, Liu,S.S. 2007, Liu et al. 2004). TEA 
provides an earlier postoperative return of gastrointestinal (GI) function (Zingg et al. 2009), 
shortens extubation time after cardiac surgery, and reduces pain scores. However, the two 
recent interpretations provide almost opposite conclusions regarding the benefit of 
postoperative TEA. A large, population-based propensity analysis observed a small 
improvement in 30-day survival and improvement in postoperative pain relief preventing 
pulmonary complications (Wijeysundera et al. 2008), while a systematic review of the 
Medline and Cochrane databases concluded that there is no evidence that perineural 
analgesia, continuous wound local anesthetics, TEA, PCA opioids, or multimodal systemic 
analgesics have any clinically significant beneficial effect on postoperative complications 
(Liu and Wu. 2007). 
Therefore, for the time being, there is no consensus regarding the beneficial effects of 
postoperative pain therapy methods on postoperative survival or morbidity. Although 
results regarding this topic have been contradictory thus far and the effects on mortality 
and major morbidity remain unproven, lessened surgical stress response and improved 
analgesia are worthy goals. 
2.3 INCIDENCE AND INTENSITY OF ACUTE POSTOPERATIVE PAIN 
AFTER CARDIAC SURGERY 
Post-sternotomy pain is often considered to be mild and to diminish quickly after the 
operation (Mueller et al. 2000, Dracup and Bryan-Brown. 1995). This belief may be based on 
the residual effects of the large doses of opioids that are traditionally administered during 
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surgery (Roediger et al. 2006). Current fast-tracking cardiac surgery regimens necessitate 
early extubation and short-acting or small doses of more conventional opioids during the 
operation. Therefore post-sternotomy pain may be very intense during the first 
postoperative hours and days. Pain has been found to be more intense during the first two 
days after cardiac surgery (Mueller et al. 2000). In a prospective study including 43 patients, 
median postoperative pain was 4 on a VAS scale of 0-10 (Nay et al. 1996) and 95% of 
patients were very satisfied or satisfied on their pain relief. The majority of patients 
expected more pain postoperatively than they actually experienced. The median duration 
of pain was 3 days (range 0-6 days) and the site of worst pain was the chest wall for 74% of 
patients. Operative techniques were not described. In a larger study (200 patients with 
median sternotomy: Mueller et al. 2000), maximal pain intensity was higher during the first 
two postoperative days (POD), being 3.7 and 3.9 on numerical rating scale (NRS) of 0-10 on 
the first and second POD, respectively, and diminishing thereafter on POD 3 and 7. Patients 
younger than 60 years of age experienced higher pain intensity compared with older 
patients. Few patients had significant pain at the saphenous vein harvesting site (between 
5.5% and 14% on POD 2 to 7). The proportion of patients not experiencing pain was 14%, 
10%, and 23% on POD 1, 2, and 7, respectively. In Meehan's prospective sample of 51 
patients, pain was moderate (≥ 4 on VAS scale of 0-10), with women experiencing more 
intense pain (4.6 compared with 3.7 among men: Meehan et al. 1995). Additionally, patients 
with internal thoracic artery (ITA) harvested for bypass graft had higher pain scores 
compared with patients who underwent vein grafting only. In a recent quality 
improvement program, pain intensity was, on average, 3.8 at rest and 4.7 maximally (Diby 
et al. 2008). During mobilization, pain was graded intense (5.0 and 6.2 on average and 
maximally, respectively). The proportion of patients that experienced no pain was 11%. 
Pain affected night sleep significantly in 68% of patients. 
2.4 INCIDENCE AND INTENSITY OF PERSISTENT POSTOPERATIVE PAIN 
AFTER CARDIAC SURGERY 
Persistent pain is currently recognized as a potential adverse outcome of cardiac surgery. 
Pain that persists after surgery may sometimes lead to severe disability. The incidence of 
chronic post-sternotomy pain after cardiac surgery varies widely between 21% and 56% 
according to various studies. This large degree of variability among different studies is 
likely due to heterogeneity in definitions and patient populations, as well as the 
retrospective nature of many investigations. There are only three prospective studies of 
chronic post-sternotomy pain after cardiac surgery (Gjeilo et al. 2010, Meyerson et al. 2001, 
King et al. 2008). One of these studies included only female patients. In that study, 18% of 
326 participating patients had pain at 12 months after surgery (King et al. 2008). The 
characteristics of pain were not described in detail. In the study conducted by Meyerson et 
al., 90 (28%) of 318 patients had post-sternotomy pain one year after operation. Forty-one 
(13%) patients reported the maximal pain to be moderate (≥ 3.0 on VAS-scale of 0-10) and 
14 patients (4%) scored the pain as severe (≥ 5.4 on VAS-scale 0-10) (Meyerson et al. 2001). 
In the latest study to include both CABG and heart valve surgery patients, 521 patients 
were questioned 6 and 12 months after heart surgery. Pain was measured using the Brief 
Pain Inventory (BPI) questionnaire and health related QOL with the Short Form 36 (SF-36). 
Persistent pain was reported by 11% of patients at 6 and 12 months after surgery. Twelve 
months after surgery, the prevalence of moderate pain was 5% and the prevalence of severe 
pain was 6% (Gjeilo et al. 2010). In multivariate analysis, older patients (grouped by 10- 
year intervals) were less likely to report persistent pain (OR 0.7, 95% CI 0.5-0.9). No other 
risk factors correlated with persistent pain. Patients with persistent pain also had lower 
health-related QOL at 12 months than patients with no pain. 
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Figure 1. Sites and mechanisms responsible for chronic postsurgical pain. 1) Denervated 
Schwann cells and infiltrating macrophages distal to nerve injury produce local and systemic 
chemicals that drive pain signalling. 2) Neuroma at the site of injury is a source of ectopic 
spontaneous excitability in sensory fibers. 3) Changes in gene expression in dorsal root 
ganglia alter the excitability, responsiveness, transmission, and survival of sensory neurons. 
4) The dorsal horn is the site of altered activity and gene expression, producing central 
sensitization, loss of inhibitory interneurons, and microglial activation, which together amplify 
sensory flow. 5) Descending brain stem controls modulate transmission in the spinal cord. 6) 
The limbic system and hypothalamus contribute to altered mood, behaviour, and autonomic 
reflexes. 7) The sensation of pain is generated in the cortex (past experiences, cultural inputs, 
and expectations converge to determine what each patient feels). 8) Genomic DNA governs 
each patient’s predisposition to chronic pain and affects their reaction to treatment. 
 
Reprinted with permission from Hehlet H et al. Lancet 2006;367:1618-25.  
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2.5 ETIOLOGY OF PERSISTENT PAIN AFTER CARDIAC SURGERY 
Persistent postsurgical pain is thought to originate mostly from surgical injury to major 
peripheral nerves, resulting in neuropathic pain, or to be a consequence of active 
inflammation (Kehlet et al. 2006). Sensory loss with paradoxical hypersensitivity of the 
affected body area with allodynia and spontaneous, sometimes paroxysmal pain are 
characteristic of neuropathic pain. Different mechanisms may damage nerves or structures 
at the spinal cord or cortical level of the nervous system, predisposing patients to persistent 
postsurgical pain (Fig. 1). 
The etiology of persistent post-sternotomy pain has not been clearly defined. Several 
different etiological factors and mechanisms are likely involved. Damage to the anterior 
ramii of the intercostal nerves may be one main reason for long-term pain after cardiac 
surgery. Intercostal nerves may be harmed during the harvest of the ITA with sternal 
retraction, or electrocautery of the pedicled or skeletonized ITA graft may cause damage to 
nerve endings or nerves (Fig. 2). Drainage tubes and sternal wires may also cause damage 
to intercostal nerves. 
 
 
 
Figure 2. Sternum elevation with a retractor during internal thoracic artery dissection in CABG 
surgery. 
 
Anterior intercostal nerve damage occurred in 73% of CABG patients with ITA 
harvesting; 15% of these patients experienced persistent postsurgical pain several months 
after surgery (Mailis et al. 2000). ITA harvesting per se has been reported to increase post-
sternotomy pain, especially in the earlier, often smaller studies (Mailis et al. 2000, Rowe and 
King. 1998); however, this predisposition to increased postoperative pain after ITA harvest 
has not been detected in the most recent larger studies (Gjeilo et al. 2010, Meyerson et al. 
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2001). Employing a skeletonizing ITA graft instead of harvesting a full-thickness pedicle 
has been proposed as one way to reduce postoperative pain, in addition to improving 
conduit flow and reducing the sternal infection rate. In a randomized, double-blind within-
patient comparison of skeletonized versus pedicled ITA, postoperative pain was similar at 
discharge and at 4 weeks after surgery, but was significantly lessened in the skeletonized 
group compared with the pedicled group 3 months after surgery (Boodhwani et al. 2006). 
In addition, sensory deficits to pinprick sensation were reduced at 4 weeks and 3 months 
(17% vs. 50%, p = 0.002) after surgery in the skeletonized side of the sternum. In contrast to 
that prospective study, skeletonizing did not reduce chronic post-CABG pain syndrome 
(PCP) in a retrospective questionnaire-based study of 380 patients at 31 months after 
surgery (Bar-El et al. 2005). PCP was present in 100/221 (45%) of patients in the skeletonized 
and 63/125 (50%) in the pedicled ITA groups, with no significant between-group difference. 
In addition to the previously mentioned etiological factors contributing to persistent 
pain after cardiac surgery, several other causes have been described. Fracture and 
migration of the steel sternal metal wire towards the skin at 3 months after cardiac surgery, 
sternal pseudoarthrosis 2 years after CABG surgery, and sternal fractures due to ITA 
harvesting or sternal retraction are associated with chronic PCP. One study (n = 71) 
described sternal wire removal as a successful technique for persistent PCP after median 
sternotomy; 86% of patients in that study reported complete or partial pain relief, while 
11% reported no change and 3% felt that symptoms had worsened (Norgaard et al. 2006). 
However, persistent pain after cardiac surgery may be a more complex syndrome than 
previously believed, and the current concept of neuropathic etiology with intercostal nerve 
damage may be too simplistic (van Leersum et al. 2010). In two recent studies, muscular 
hyperalgesia, upper extremity pain, and dysthesias in the form of diminished or heightened 
abnormal sensation occurred in large number of PCP patients (van Leersum et al. 2010, 
Alston and Pechon. 2005). In a retrospective study including 189 patients with chronic post-
sternotomy pain, patients with PCP also had musculoskeletal pain in the trunk, upper 
extremities, head, and neck if they experienced tenderness of the sternum. This study refers 
to the finding that there may be different varieties of PCP (van Leersum et al. 2010). 
Altogether, at the moment, the definite etiology of PCP remains ambiguous.  
2.6 OPIOID TOLERANCE AND HYPERALGESIA AFTER SURGERY 
Opioid tolerance has been defined as a progressive reduction in the analgesic effect of an 
opioid analgesic, or alternatively as a need for increasing opioid dosing for a given pain 
stimulus (McQuay. 1999, Koob and Bloom. 1988). It was traditionally thought to occur 
during opioid therapy that was prolonged for days or weeks. However, recent studies have 
demonstrated the rapid occurrence of opioid tolerance during continous opioid infusion in 
animals and human volunteers, as well as in surgical patients (Kissin et al. 1991b, Guignard 
et al. 2000, Crawford et al. 2006). The propensity of opioids to induce analgesic tolerance 
(also defined as a reduction in responsiveness to an agent after repeated exposure) 
profoundly limits their usefulness. 
Opioid tolerance appears to be unrelated to the relative potency of opioid agents (Kissin 
et al. 1991a), but is more likely to occur with short-acting opioids and larger opioid doses. 
The modality of pain is also a factor. In addition, the use of several pharmaceuticals may 
modify subsequent opioid tolerance whether the drugs are administered before or after 
opioid exposure. In particular, pain per se has been reported to attenuate acute opioid 
tolerance in experimental studies (Ho et al. 1999); neuropathic and inflammatory pain have 
also been shown to inhibit morphine-induced tolerance, possibly through central 
mechanisms, in a rodent model in which morphine was administered daily for five days 
(Iwai S et al. 2012). Inflammation appears to prevent the development of tolerance, at least 
in peripheral opioid receptors after prolonged morphine treatment (Zollner et al. 2008). 
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In practice, opioid tolerance may lead to greater opioid requirements and increasing 
postoperative pain. Opioid tolerance has appeared in some clinical studies (Table 1); 
however, studies do exist in which opioid tolerance has not been demonstrated (Table 2). 
 
Table 1. Studies in which remifentanil induced opioid tolerance in humans. The duration of 
remifentanil infusion is presented as mean (SD) or median (range), depending on the original 
publication. 
 
Author Subjects (n) Remifentanil dosing Duration of 
remifentanil infusion 
Min (SD/range) 
Vinik HR (1998) healthy volunteers (13) 0.1 µg/kg/min 240 
Guignard B (2000) 
major abdominal surgery 
(24) 0.3 ± 0.2 µg/kg/min 
294 (252 - 348) 
Guignard B (2002) abdominal surgery (25) 0.28 µg/kg/min 264 (240 - 312) 
Koppert W (2003) healthy volunteers (13) 0.1 µg/kg/min 30 
Hansen EG (2005) 
major abdominal surgery 
(21) 0.4 µg/kg/min 
161 (124 - 231) 
Joly V (2005) 
major abdominal surgery 
(25) 0.4 µg/kg/min 
258 (186 -276) 
Crawford MV (2006) 
pediatric scoliosis surgery 
(15) 0.28 ± 0.04 µg/kg/min 
466 (SD 57) 
Collard V (2007) 
laparoscopic 
cholecystectomy (30) 0.1 – 0.5 µg/kg/min 
80 (70 - 90.5) 
 
 
Table 2. Studies in which remifentanil did not induce opioid tolerance in humans. The duration 
of remifentanil infusion is presented as mean (SD) or median (range), depending on the original 
publication. 
 
Author Subjects (n) Remifentanil dosing Duration of 
remifentanil infusion 
min (SD/range) 
Schraag S (1999) orthopedic surgery (30) target controlled  2 ng/ml 360 (252 - 348) 
Cortinez  (2001) gynecologic surgery (30) 0.1 µg/kg/min  116 (34) 
Gustorff B (2002) healthy volunteers (20) 0.08 µg/kg/min 118 
Lee LYH (2005) colorectal surgery (30) 0.17 µg/kg/min 162.5 (52 - 448) 
Rauf K (2005) CABG (10) 0.1 µg/kg/min 499.4 (80) 
Angst MS (2009) healthy volunteers (36) o.65-1.3 µg/kg/min 180 
 
Opioids reduce pain transmission presynaptically by reducing neurotransmitter release, 
and postsynaptically by hyperpolarizing the projection neuron. Exogenous or endogenous 
opioids act through neuronal membrane-bound opioid receptors (µ-, δ-, and κ-receptors). 
The µ-opioid receptor is primarily responsible for opioid-induced analgesia and tolerance. 
Upon activation by opioids, these receptors are coupled to inhibitory G-proteins, reducing 
calcium and sodium currents and substance P release (Fig. 3). Therefore, alterations in 
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excitatory amino acids during neuropeptide release, opiate receptor activity, or intracellular 
messenger activity may reduce the opioid effect and lead to opioid tolerance (Rozenfeld et 
al. 2007). 
The underlying mechanism behind opioid tolerance has not yet been established. Many 
mechanisms have been proposed, including reduced internalization and recycling of opioid 
receptors, a lower degree of µ-receptor phosphorylation, adenylyl cyclase/cAMP-related 
cellular adaptations, and the enhancement of N-methyl-D-aspartate (NMDA) receptor 
function. One theory behind morphine tolerance is the heterodimerization of µ- and δ-
opioid receptors (Rozenfeld et al. 2007). Prolonged morphine administration has been 
shown to increase the insertion of δ-opioid receptors into the plasma membrane, and µ- and 
δ-opioid receptor heterodimers induce fewer responses than µ-opioid receptor 
homodimers. Delta-opioid receptors appear to be critical for the development of morphine 
tolerance (Zhao and Joo. 2008). 
It was recently observed that the platelet-derived growth factor receptor-β (PDGFR-β)–
mediated pathway is involved in inducing morphine tolerance (Wang et al. 2012). The 
involvement of PDGFR-β was demonstrated experimentally in µ-opioid receptor–
transfected glioma cells. PDGFR-β inhibition by imatinib also eliminated morphine 
tolerance in rats in that investigation. Although the mechanism by which imatinib 
eliminates opioid tolerance is unclear, imatinib is in widespread clinical use and might offer 
a clinically feasible treatment option for morphine-induced opioid tolerance if proven 
clinically effective. 
Hyperalgesia may present after surgery due to central sensitization by surgical 
nociceptive stimuli or drug-induced hyperalgesia. Opioid-induced hyperalgesia is defined 
as more pain accompanying a given stimulus in patients who are given opioids to control 
their pain. In this setting, opioids initially provide an analgesic effect, but repeated dosing 
subsequently activates pronociceptive facilitatory pathways, leading to increased central 
nervous system sensitivity, hyperalgesia, and increased pain. The diagnosis and 
quantification of postoperative hyperalgesia is clinically difficult. By definition, opioid-
induced hyperalgesia presumes a standard pain stimulus, necessitating the determination 
of a stimulus dose-response curve in a process termed quantitative sensory testing (Wilder-
Smith and Arendt-Nielsen. 2006). Therefore, postoperative hyperalgesia is likely to be 
unrecognized in the postoperative setting and may have deleterious consequences 
regarding postoperative recovery. Opioid-induced hyperalgesia reduces the analgesic 
efficacy of subsequent opioid dosing, and may predispose patients to persistent 
postoperative pain, thereby increasing its incidence. 
The modalities that induce the development of opioid-induced hyperalgesia are not 
entirely clear; however, they might consist of high doses, long-term treatment, or sudden 
changes in concentration (Wilder-Smith and Arendt-Nielsen. 2006). The type of nociceptive 
input (e.g., experimental pain, surgery) and duration of nociception (i.e., persistent or short-
acting), as well as the patient’s age, sex, and genetic predispositon, may alter hyperalgesic 
response. After all, hyperalgesia may be the net result of central or descending facilitation, 
or it may be induced by deficient inhibitory mechanisms (Wilder-Smith and Arendt-
Nielsen. 2006). 
Whether hyperalgesia and opioid tolerance are truly separate phenomena remains 
controversial. However, this distinction is of clinical significance in that opioid tolerance 
can be managed by increasing dosing, while in cases of hyperalgesia the opioid dose should 
be reduced and the use of alternative analgesics should be attempted. In a novel clinical 
study of 103 opioid naϊve patients with low back pain, patients developed opioid tolerance 
to remifentanil after one month of oral morphine therapy; however, no signs of opioid 
hyperalgesia based on cold pain or heat pain testing developed (Chu LF et al 2012). Based 
on this information, the authors of the study suggested that opioid tolerance, rather than 
hyperalgesia, might be a more likely consequence of moderately dosed morphine therapy 
(75 mg/d) administered for a limited time period (one month). In contrast, a 75-patient 
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study by Joly et al. demonstrated postoperative hyperalgesia in patients who received a 
large dose of remifentanil compared with a low dose after abdominal surgery (Joly et al. 
2005). In the same study, the authors detected hyperalgesia by von Frey hair stimulation 
without differences in pain or pressure pain detection. Although postoperative morphine 
consumption was also increased, greater opioid requirements and hyperalgesia were 
abolished by ketamine infusion. 
Ondansetron, a 5-hydroxytryptamine type 3 receptor antagonist, was recently shown to 
prevent or reverse morphine-induced hyperalgesia and opioid tolerance, and to suppress 
morphine-induced increases of multiple genes associated with opioid-induced hyperalgesia 
and tolerance in the dorsal root ganglia and spinal cord of mice. If clinical studies confirm 
these findings, 5-hydroxytryptamine type 3 receptor antagonists are readily available for 
clinical use; they have already proven safe for the widespread treatment of nausea and 
vomiting. 
 
 
 
Figure 3. Opioid receptor signaling and transport in primary afferent neurons. Opioid receptors 
and neuropeptides (such as substance P) are synthesized in the dorsal root ganglion and 
transported along intra-axonal microtubules into central and peripheral processes of the 
primary afferent neuron. At the terminals, opioid receptors are incorporated into the neuronal 
membrane and become functional receptors. Upon activation by exogenous or endogenous 
opioids, opioid receptors couple to inhibitory G-proteins. This leads to direct or indirect 
(through decrease of cyclic adenosine monophosphate) suppression (-) of Ca2+ or Na+ 
currents, and subsequent attenuation of substance P release. The permeability of the 
perineurium is increased within inflamed tissue. OR, opioid receptor; sP, substance P; EO, 
exogenous opioids; OP, endogenous opioid peptides; Gi/o, inhibitory G proteins; cAMP, cyclic 
adenosine monophosphate. 
 
Reprinted with permission from Stein C et al. Nature Medicine 2003;9:1003-8. 
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2.7 REMIFENTANIL-INDUCED OPIOID TOLERANCE 
Remifentanil is a unique opioid analgesic with a rapid onset and an ultra-short duration of 
action. Remifentanil has a terminal half-life of 10 min; its context-sensitive half time (i.e., the 
time necessary for the plasma concentration to decrease by 50% after an infusion of varying 
duration to maintain a steady state concentration) is approximately 3 min, which remains 
constant regardless of the duration of the infusion. Remifentanil is considered 
advantageous in surgery with intense painful stimuli and early postoperative extubation, 
such as fast-tracking cardiac surgery. Remifentanil is commonly used in cardiac surgery 
with widely variable dosing ranging from 0.1 to 5 µg/kg/min. However, its perioperative 
use has raised concern after reports indicating higher pain scores and exaggerated 
postoperative opioid requirements, suggesting the development of acute opioid tolerance 
and opioid-induced hyperalgesia (Guignard et al. 2000, Crawford et al. 2006, Joly et al. 
2005). These effects may be dependent on the total dose of remifentanil administered, as 
well as on what anesthetics are used during surgery, whether they are pungent or 
intravenous (Kingston et al. 2006, Shin et al. 2010, Cheng et al. 2008). 
Remifentanil is exceptional in its ability to directly activate NMDA receptors expressed 
experimentally in frog oocytes, an effect that was not detected after the use of fentanyl 
(Hahnenkamp et al. 2004). Furthermore, this effect is inducible by δ-opioid receptor 
activity. Rapid development of remifentanil-induced opioid tolerance is well established in 
animals (Kissin et al. 1991b). Studies in human volunteers have been inconsistent. In cold 
water and pressure pain tolerance tests, remifentanil infused at a constant rate of 0.1 
µg/kg/min for 4 h developed acute tolerance to the analgesic effect (Vinik and Kissin. 1998). 
The analgesic effect was reduced to one-fourth of the peak value after 3 h. In contrast, a 3-h 
continous infusion of remifentanil at 0.08 µg/kg/min did not induce opioid tolerance in 20 
healthy volunteers (Gustorff et al. 2002). This study was conducted with heat, cold, and 
electrical pain perception threshold tests in a placebo-controlled crossover fashion. Studies 
in which remifentanil did or did not induce opioid tolerance are summarized in Tables 1 
and 2. 
Altogether, it appears that remifentanil is able to induce opioid tolerance and 
hyperalgesia both experimentally and clinically. However, these untoward adverse effects 
may be prevented by lower dosing or the co-administration of an NMDA antagonist (Joly 
et al. 2005). 
2.8 PAIN TREATMENT AFTER CARDIAC SURGERY 
2.8.1 Pharmacological therapy 
Pain therapy after cardiac surgery is presently far from optimal. In contrast to the 
overwhelming range of pain treatment trials after non-cardiac surgery, studies of 
postoperative analgesia after cardiac surgery have been rare (Roediger et al. 2006). 
Parenterally administered (im., i.v.) opioids have been the mainstay of pain therapy after 
cardiac surgery for decades (Roediger et al. 2006). Recently, to reduce the well known 
adverse effects of opioids, NSAIDs and paracetamol have been added to pain therapy after 
cardiac operations (Nussmeier et al. 2005, Pettersson et al. 2005). Attempts to compensate 
for reduced opioid dosing during surgery include local analgesic infusions, regional 
analgesia techniques, and introducing new adjuvants to opioid therapy (Priestley et al. 
2002, White et al. 2003, Pesonen et al. 2011). 
2.8.1.1 Opioids 
The analgesic effects of opioids have been clearly established. Currently opioid receptors 
are classified as µ (mu), δ (delta) and κ (kappa) receptors. Different opioid analgesics vary 
with regard to their affinity to opioid receptors, and therefore also have a variety of 
pharmacodynamic properties. Clinically, and especially in cardiac surgery, the most 
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popular opioid analgesic has traditionally been morphine. However, in Finland the 
synthetic thebaine derivative oxycodone (6-deoxy-7,8-dihydro-14-hydroxy-3-O-methyl-6-
oxymorphone) is the most commonly used opioid for postoperative pain (Pöyhiä. 1994). 
Oxycodone has affinity for both µ- and κ-opioid receptors, and its mean elimination half-
life is 222 min after an i.v. dose. Because oxycodone does not liberate histamine, it may be 
more cardiovascularly stable than morphine. The analgesic potency of oxycodone appears 
to be similar to that of morphine (Pöyhiä et al. 1993). 
Opioids have thus far been administered mostly by i.m. or i.v. injections. Intermittent 
i.m. dosing leads to unnecessarily high peak concentrations and long periods without 
necessary pain relief while the opioid concentration is diminishing. Therefore, frequent 
nurse-controlled i.v. dosing or PCA offer better analgesia, maintaining the desired target 
drug concentration more efficiently in the blood. Postoperative PCA-opioid dosing is 
unlikely to offer true benefits in patient rehabilitation after cardiac surgery. Two relatively 
small studies have shown improved pulmonary function and reduced atelectasis scores 
with PCA compared with nurse controlled analgesia (NCA) after cardiac surgery (Gust et 
al. 1999, Boldt et al. 1998). In a meta-analysis published in 2006, PCA reduced postoperative 
pain after cardiac surgery; 48-h VAS scores were reduced by 25% (absolute VAS difference 
0.7) with increased opioid consumption by 7 mg at 24 postoperative hours and 10 mg at 48 
postoperative hours (Bainbridge et al. 2006b), although the use of PCA did not significantly 
improve patient satisfaction scores or postoperative complications. 
Opioids appear to be more effective during rest than during mobilization or coughing 
(i.e., during dynamic pain) (Tverskoy et al. 1996), this was especially well shown after 
cardiac surgery (Milgrom et al. 2004). Pure µ-opioid agonists have no ceiling effect (i.e., 
with increasing dose their analgesic efficacy increases). Nevertheless, clinically they possess 
several adverse effects that restrict their usefulness, especially in large doses. Respiratory 
depression, sedation, nausea and vomiting, pruritus, and gastrointestinal atony limit 
postoperative opioid administration. Opioid-induced tolerance and hyperalgesia may also 
limit their feasibility and dosing in clinical practice (Guignard et al. 2000, Crawford et al. 
2006, Joly et al. 2005). Despite opioids’ well known adverse effects, parenterally 
administered opioids remain the most important analgesics after cardiac surgery. 
2.8.1.2 Paracetamol 
Paracetamol (N-acetyl-p-aminophenol) is an acetanilide derivative with the molecular 
formula C8H9NO2. It is likely the most commonly used analgesic worldwide. The primary 
mechanism of action by which paracetamol reduces fever and pain is ambiguous. 
Paracetamol may act by inhibiting prostaglandin synthesis, by increasing descending 
serotonergic impulses that are antinococeptive, or by indirectly activating cannabinoid CB1 
receptors. Paracetamol appears to possess negligent peripheral activity and it has been 
suggested that its nociceptive effect is mainly central, with almost no anti-inflammatory 
action in peripheral tissues (Smith 2011). Paracetamol is considered a safe analgesic, 
although it carries a risk of hepatotoxicity at higher doses and has been reported to slightly 
impair thrombocyte function (Munsterhjelm et al. 2005). The efficacy of paracetamol as an 
analgesic has been established in many studies, with a number needed to treat (NNT) of 3.8 
for 50% pain relief over 4-6 h compared with placebo using a 1000-mg dose (Oscier and 
Milner 2009). 
Paracetamol is recommended as a component of multimodal perioperative analgesia by 
the American Society of Anesthesiologists (American Society of Anesthesiologists Task 
Force on Acute Pain Management. 2004), and is used routinely as an analgesic adjunct after 
cardiac surgery. The most popular routes of paracetamol administration are oral tablets and 
rectal suppositories. However, rectal or oral administration of paracetamol may not be 
optimal after cardiac surgery, basically due to unpredictable and incomplete absorption. 
Schuitmaker et al. (1999a) found that two grams of paracetamol administered via 
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nasogastric tube or suppository resulted in blood concentrations below 10 mg/l, which is 
considered an analgesic level. 
Propacetamol is an i.v.-administered prodrug of paracetamol. Propacetamol is 
completely hydrolyzed to paracetamol in seven min after i.v. injection. Substantial 
concentrations of paracetamol are detectable in cerebrospinal fluid 20 min after a 2-g 
infusion of propacetamol (Bannwarth et al. 1992). Propacetamol has been shown to reduce 
opioid requirements and pain scores in several studies after gynecologic and orthopedic 
surgery (Zhou et al. 2001, Hernandez-Palazon et al. 2001). The benefit in pain therapy has 
not been clarified after cardiac surgery (Ranucci et al. 1999 and Avellaneda et al. 2000). 
Presently, a ready-to-use preparation of i.v. paracetamol solution is widely available and 
has replaced propacetamol, which has been associated with the adverse effects of skin 
irritation and contact dermatitis among nursing staff. I.v. paracetamol has proven efficacy 
in oral and orthopedic surgery (Moller et al. 2005a, Moller et al. 2005b, Sinatra et al 2005). 
Cattabriga et al. compared i.v. paracetamol to placebo, starting with 1 g of paracetamol 25 
min before the end of surgery and administered every 6 h thereafter for 72 h total in 113 
cardiac surgery patients. Standard analgesia included tramadol and rescue morphine as 
needed (VAS >3). Pain was reduced in the paracetamol group at rest at 12 to 24 
postoperative hours; during deep breath there was a significant difference only at 12 h 
favoring the paracetamol group (Cattabriga et al. 2007). The groups did not differ 
significantly regarding the postoperative cumulative morphine requirement, although the 
dose was apparently lower in the paracetamol group (48 vs. 97 mg; the median value was 5 
mg in both groups). The results of this study are ambiguous, and are not explained in the 
article. 
Pettersson et al. evaluated oral and i.v. administration of paracetamol in 77 CABG 
patients, and observed a lower postoperative opioid requirement in the i.v. group (17 vs. 22 
mg); however, VAS scores did not differ between groups (Pettersson et al. 2005). In another 
study, the combination of diclofenac and paracetamol was compared with diclofenac alone 
or placebo in 60 patients after CABG surgery. Diclofenac + paracetamol reduced PCA-
morphine consumption by 45% compared with diclofenac alone during 24 h (12 vs. 22 mg) 
(Fayaz et al. 2004). Active treatment groups exhibited lower pain scores at 12 and 24 
postoperative hours, shorter extubation times, better oxygenation, and less nausea and 
vomiting (41% and 56% reduction, respectively) than the placebo group. Based on these 
studies, paracetamol appears to have an opioid sparing effect, and may reduce 
postoperative pain and opioid-related adverse effects after sternotomy. However, the 
magnitude and duration of efficacy have been questioned, especially in the context of 
severe postoperative pain. For example, in a large study of 550 patients, 155 experienced 
severe pain with VAS 57 mm (0-100 mm) and an 18% decrease in postoperative morphine 
requirement after orthopedic, abdominal, or gynecological surgery (Aubrun et al. 2003). 
Similarly, a recent systematic review and a mixed treatment comparison analysis found 
only a 6-mg reduction of 24-h morphine consumption and no reduction in nausea and 
vomiting for postoperative paracetamol administration compared with placebo. Therefore, 
authors concluded that paracetamol does not confer much benefit regarding reduced 
morphine consumption during the first 24 postoperative hours (Maund et al. 2011b) The 
true efficacy of paracetamol analgesia after cardiac surgery remains to be elucidated. 
2.8.1.3 NSAIDs 
NSAIDs have been widely used after non-cardiac surgery and have been accepted as part 
of the routine postoperative analgesic regime. The benefits of combining NSAIDs with pain 
therapy are better pain relief, reduced opioid requirements and opioid-induced adverse 
effects, and improved patient satisfaction; however, only some studies have reported 
reduced complications after surgery, and such reports are even more rare in cardiac 
surgery (Maund et al. 2011a, Fayaz et al. 2004, Elia et al. 2005, Bainbridge et al. 2006a). 
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Traditionally, postoperative NSAID use has been avoided after cardiac surgery. The 
main reasons for reluctance regarding NSAID use in this context are predisposition for 
renal insufficiency and increased postoperative bleeding when cardiopulmonary bypass 
has been utilized. 
There have been some reports on NSAID therapy after heart surgery. In one small 
study, indomethacin was reported to ensure better pain relief than placebo after CABG. In 
that report, reduced opioid consumption (38%) and lower VAS pain scores (26% to 66%) at 
rest, but not during coughing, were observed when two doses of indomethacin were 
administered rectally after cardiac surgery (Rapanos et al. 1999). Hynninen compared 75 
mg diclofenac, 100 mg ketoprofen, 100 mg indomethacin, and placebo administered 1 h 
before tracheal extubation and 12 h later after CABG. Only patients who received 
diclofenac required less morphine and had lower pain scores than the placebo group 
(Hynninen et al. 2000). Accordingly, Fayaz et al. (2004) and Maddali et al. (2006) also 
observed reduced postoperative opioid need after rectal diclofenac administration. The 
study by Fayaz et al. reported a 10 mg (27%) reduction in cumulative morphine 
consumption at 24 postoperative hours, and marginally but statistically lower pain scores at 
12 and 24 postoperative hours in the diclofenac group compared with the placebo group. 
Shorter extubation time (487 vs. 710 min) and better PaO2 after extubation were also 
observed in that study. Similarly, in Maddali’s study the duration of mechanical ventilation 
was significantly shorter among patients who were postoperatively administered 
diclofenac compared with those administered fentanyl or remifentanil infusion. Several 
other NSAIDs have demonstrated fairly good pain relief and an opioid-sparing effect after 
cardiac surgery (Kulik et al. 2004, Khalil et al. 2006); however, negative findings have also 
been published. Nimesulide, a COX-2 inhibitor, was judged ineffective, although there was 
a small opioid sparing effect of 9.0 mg (95% CI -28.9 to 10.9 mg) with no differences in pain 
scores (Harney et al. 2008). A single dose of etodolac administered via nasogastric tube at 
the end of surgery reduced pain scores only immediately after extubation, but not at 24 
postoperative hours, and no opioid sparing effect was observed (Koizuka et al. 2004). In 
contrast, oral etodolac (300 mg) and diclofenac (50 mg) offered better pain relief, reduced 
additional pain medication, and were associated with fewer side effects than oral tramadol 
(150 mg) administered every 8 h during the second and third POD after CABG surgery. 
COX-2 inhibitors parecoxib and valdecoxib have been evaluated in CABG surgery in 
two large studies (Ott et al. 2003, Nussmeier et al. 2005). However, serious adverse events 
occurred more frequently: 7.4% of patients in the two study medication groups vs. 4.0% in 
the placebo groups experienced serious adverse events. In particular, the cardiovascular 
adverse events myocardial infarction, cardiac arrest, stroke, and pulmonary embolism were 
more frequent among patients who received parecoxib and valdecoxib than among patients 
who received placebo (2.0% vs. 0.5%). In a recent meta-analysis regarding the use of non-
selective NSAIDs in cardiothoracic surgery, no increased adverse event incidence was 
observed (Bainbridge et al. 2006a). That analysis included 20 randomized trials and one 
abstract, and involved 1065 patients total. A small (5 mg) reduction in morphine 
consumption was observed. The opioid-sparing effect was surprisingly small, and was less 
in cardiac surgery than in thoracic surgery in that analysis. Furthermore, no reduction in 
opioid-related adverse effects was detected (Bainbridge et al. 2006a). 
Therefore, COX-2 inhibitors are currently not recommended. Non-selective NSAIDs should 
also be administered with caution after cardiac surgery, and only to carefully selected 
patients. 
2.8.1.4 Ketamine 
Ketamine was developed as a general anesthetic and has been utilized clinically for over 30 
years. Recently, ketamine has become popular in subanesthetic doses as an analgesic 
adjunct to postoperative opioid-based pain therapy. Ketamine works as a noncompetitive 
antagonist of NMDA receptors, and has been shown to prevent opioid-induced analgesic 
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tolerance and hyperalgesia (Joly et al. 2005, Kissin et al. 2000, Laulin et al. 2002, Stubhaug et 
al. 1997). Numerous studies have demonstrated the opioid-sparing effect and acute pain 
alleviation associated with ketamine (Aveline et al. 2009, Guignard et al. 2002, 
Himmelseher et al. 2001, Kollender et al. 2008, Suzuki et al. 2006). In addition, ketamine has 
been shown to reduce postoperative pain and opioid requirements in three systematic 
reviews (Subramaniam et al. 2004, Elia and Tramer. 2005, Bell et al. 2006a). However, there 
are also numerous studies that show no effect of ketamine as a postoperative analgesic 
(Jaksch et al. 2002, Jensen et al. 2008). Despite the beneficial analgesic effects, ketamine is 
associated with psychotomimetic adverse effects, which have reduced the clinical feasibility 
of the racemic compound. S(+) – ketamine, the s-isomer of ketamine, has been suggested to 
improve analgesia with fewer cognitive adverse effects than the racemic mixture. However, 
these proposed more advantageous properties of S(+)- ketamine have not been clearly 
established clinically. Therefore, ketamine's position in postoperative analgesia remains 
unclear. 
There are surprisingly few studies of ketamine in cardiac surgery. Nesher et al. 
evaluated 58 patients undergoing anterolateral thoracotomy for minimal invasive direct 
coronary artery bypass (MIDCAB), lung tumor resection, or median sternotomy for off 
pump coronary artery bypass (OPCAB). Patients were randomized to receive morphine or 
morphine + ketamine (MK) i.v. patient-controlled analgesia (iv-PCA). The ketamine group 
received a one-third smaller dose of morphine + 5 mg of ketamine per iv-PCA dose. The 
ketamine group exhibited lower pain scores, and had lower morphine consumption 
(Nesher et al. 2008). Diclofenac was used 70% more in morphine than in morphine + 
ketamine patients. Morphine patients suffered more postoperative nausea and vomiting. 
No hallucinations emerged. In a following study ketamine combined with two-thirds of the 
standard morphine dose provided equivalent analgesia during 4 postoperative hours after 
thoracotomy compared with the standard morphine dose (Nesher et al. 2009). 
Ketamine may also offer other potentially beneficial properties in cardiac surgery. 
Specifically, it has been reported to reduce delirium after cardiopulmonary bypass (CPB), 
possess antidepressive properties, and offer anti-inflammatory effects with the inhibition of 
tumor necrosis factor alpha and interleukin 6 (Hudetz et al. 2009a, Welters et al. 2011). 
However, although the delirium-reducing effect was significant in the Hudetz study, with 
incidence rates of 1/29 among ketamine-treated patients and 9/29 among patients with 
delirium in the placebo group (odds ratio 12,6; 95% CI 1.48-107.5; p = 0.01), the sample size 
was very small. Ketamine has previously been shown to suppress the systemic 
inflammatory reaction associated with CPB (Bartoc et al. 2006). Whether ketamine offers 
true neuroprotection during and after CPB remains to be proven. 
2.8.1.5 Magnesium 
It has been suggested that magnesium sulfate possesses analgesic properties related to the 
calcium channel antagonist effect and blocking the NMDA channel, which (as an excitatory 
amino acid receptor) mediates opioid tolerance, hyperalgesia, and persisting pain states. 
However, it is unclear whether the analgesic effect of magnesium sulfate is exerted through 
central or peripheral mechanisms, because it is difficult to achieve cerebrospinal 
concentrations that are high enough for the modulation of analgesia via NMDA inhibition. 
Magnesium has a demonstrated opioid-sparing postoperative effect after orthopedic and 
gynecological surgery (Dabbagh et al. 2009, Ryu et al. 2008). In an unblinded study in 
CABG patients, magnesium sulfate was administered with 2 g/70 kg bolus and 2g/70 kg/d 
continuous infusion for three days (Bolcal et al. 2005). The two control groups were given 
either codeine or diclofenac by nasogastric tube for three days. The magnesium group had 
lower pain scores and less morphine consumption during the first two postoperative days. 
However, limitations in that study included the unsure absorption of codeine and 
diclofenac, and the administration of subcutaneous morphine on-demand if VAS was 
greater than 5. In another study, 40 patients undergoing CABG or heart valve surgery were 
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randomized to receive postoperatively a 0.2 mmol/kg i.v. bolus of magnesium gluconate (86 
mg/kg) followed by infusion of 0.03 mmol/kg/h or placebo for 12 h after extubation. Pain 
was treated with a remifentanil infusion titrated according to pain intensity score. 
Magnesium moderately reduced the remifentanil requirement and lowered pain scores 
after surgery. Dose reductions of remifentanil infusion were needed more frequently 
among magnesium-treated patients than among patients who received placebo, due to slow 
breathing frequency (Steinlechner et al. 2006). In the most recent and largest study of 
magnesium in CABG surgery, 218 patients were prospectively randomized to receive a 
0.032 mmol/kg/h, 24-h MgSO4 infusion or placebo, starting after anesthesia induction 
(Ferasatkish et al. 2008). The cumulative morphine consumption was remarkably low in 
both groups (14 mg in magnesium-treated patients vs. 20 mg in the placebo group). Pain 
scores were also lower among magnesium-treated patients than among patients 
administered placebo, but only marginally, and the extubation time was 74% shorter. 
Notably, postoperative morphine administration was nurse-controlled and morphine was 
administered whenever an individual’s VAS score was >3 (on a scale of 0-10). Two patients 
in the magnesium group had severe bradycardia accompanied by hypotension, and were 
withdrawn. These three studies show that magnesium may be a beneficial adjuvant to 
opioid analgesia, although high dosing may be necessary. Knowing the tendency of 
patients to be hypomagnesemic after CPB, magnesium infusion may be warranted 
postoperatively for many reasons. 
2.8.1.6 Gabapentin 
Gabapentin was developed as an antiepileptic drug that is currently used to treat chronic 
neuropathic pain, and recently also postoperative pain. Gabapentin is a 3-alkylated 
analogue of gamma-amino-butyric acid (GABA), and its suggested analgesic mechanism 
may involve decreasing neurotransmitter release through a calcium-dependent mechanism 
or NMDA-mediated reduction of the glutamate releasing mechanism. In a recent 
systematic literature review, gabapentin exhibited an opioid-sparing effect postoperatively, 
ranging from 20% to 62% during the first 24 h after a single gabapentin dose of 300-1200 mg 
(Zhang et al. 2011). This opioid-sparing effect corresponded with 30 ± 4 mg (mean ± 95% CI) 
of morphine administration during the first 24 h after surgery. Notably, gabapentin was 
especially beneficial regarding movement-related dynamic pain, possibly through its ability 
to prevent central sensitization. Gabapentin was also able to reduce opioid-related adverse 
effects, with few adverse effects of its own. 
In cardiac surgery, gabapentin was compared with placebo in a prospective study of 60 
CABG patients. Gabapentin was administered as a single oral dose of 600 mg 2 h before 
operation. Total PCA-morphine consumption was 57% lower in the gabapentin group (6.7 
mg) than in the placebo group (15.5 mg) at 24-h (Menda et al. 2010). Thus, morphine 
consumption was surprisingly low in both groups in this study. Pain scores (VRS) at rest 
during the total 24-h study period and during coughing were also lower in the gabapentin 
group than in the placebo group at 2, 6, and 12 h. Accordingly, nausea was reduced in 
gabapentin patients; however, there were more over-sedated patients and mechanical 
ventilation was prolonged approximately 1 h in the gabapentin group compared with the 
placebo group. 
In another recent small study, 40 patients received 1.2 g of gabapentin or placebo 1 h 
before surgery and once daily on the first two postoperative days. Pain scores on the first 
three postoperative days were significantly lower in the gabapentin group than in the 
placebo group; rescue tramadol consumption was also less, 99 mg vs. 149.4 mg (Ucak et al. 
2011). Adverse effects were not increased in the gabapentin group compared with the 
placebo group. There was no between-group difference in the intensity of persistent 
postoperative pain at 1 and 3 months after surgery. 
In contrast to the previous studies, 1.2 g of gabapentin 2 h preoperatively and 600 mg 
twice a day thereafter did not reduce postoperative fentanyl in 48 h and did not diminish 
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pain at rest or on movement in a study of 60 patients undergoing cardiac surgery (Rapchuk 
et al. 2010). Adverse effects were also similar in both groups. The results of these three 
studies are contradictory. However, gabapentin may be a useful adjunct to opioid analgesia 
after cardiac surgery, especially if rapidly eliminated anesthetics (e.g., remifentanil and 
sevoflurane) are utilized during operation. 
2.8.1.7 Pregabalin 
Pregabalin is a structural analogue of the inhibitory neurotransmitter GABA. Its mechanism 
of action is similar to GABA: it binds to calcium channels, reducing the release of excitatory 
neurotransmitters and hindering the development of hyperalgesia and central sensitization. 
Pregabalin is substantially more potent than gabapentin and has a more favorable adverse 
event profile. In a recent meta-analysis, pregabalin exhibited opioid-sparing effects of 9 mg 
at doses <300 mg and 13 mg at doses >300 mg (Zhang et al. 2011). Postoperative pain 
intensity was not reduced; however, only minor surgery was involved, with a low level of 
postoperative pain. 
Pregabalin has been evaluated in one prospective, randomized study including 70 cardiac 
surgery (CABG or valve surgery) patients aged 75 years or older. Pregabalin administered 
as 150 mg preoperatively and 75 mg twice daily for 5 PODs reduced postoperative 
oxycodone consumption by 44% (9 mg in the pregabalin-treated group and 16 mg in the 
placebo group) in 24 h (Pesonen et al. 2011). The total oxycodone consumption during 5 
postoperative days was also 48% lower and the percentage of patients with a verbal rating 
scale (VRS) > 2 (on a scale of 0-4) was lower at 2, 10, and 12 postoperative hours in the 
pregabalin-treated group compared with the placebo group. The sedation scores and 
incidence of nausea and vomiting did not differ between the groups. Persistent pain at rest 
was similar between the groups at 1 and 3 months after surgery; however, pain during 
movement was somewhat reduced in pregabalin-treated patients compared with the 
placebo group (VRS ≥ 1 in 1/27 pregabalin-treated patients vs. in 7/30 patients in the 
placebo group). Based on this single publication, pregabalin may be a beneficial adjunct in 
the context of acute postoperative pain after cardiac surgery, while its position in reducing 
persistent pain after cardiac surgery remains to be clarified. 
2.8.2 Regional analgesia 
2.8.2.1 Intrathecal analgesia 
Intrathecal (IT) opioid receptors in the substantia gelatinosa of the spinal cord make the 
administration of IT morphine a more attractive analgesic technique than i.v. 
administration. Injecting opioid closer to the structures where it acts makes analgesia more 
powerful, allowing the use of lower doses of opioids with the potential to achieve more 
intense analgesia. Potential benefits of IT morphine in cardiac surgery include attenuated 
stress response, improved respiratory function, prolonged postoperative analgesia, and 
better outcome. IT opioid administration via lumbar puncture (at L2-3 or L3-4 level) is 
considered an easy, quick, reliable, and relatively safe procedure. It was first described in 
cardiac surgery by Mathews and Abrams in 1980 (Mathews and Abrams. 1980). Since then, 
several studies have employed various dosing of spinal morphine, as well as various 
anesthesia regimens during cardiac surgery. Most studies have focused on postoperative 
analgesia. However, respiratory depression in the context of early extubation is a specific 
concern with spinal morphine. Hence, a Society of Cardiothoracic Anesthesiologists (SCA) 
survey in 2001 indicated that IT techniques were used by only 8% of anesthesiologists 
(Goldstein et al. 2001). 
IT analgesia has been evaluated in three systematic reviews and one meta-analysis 
(Chaney. 2006, Richardson et al. 2009, Meylan et al. 2009, Liu et al. 2004). Anesthesia and 
administered morphine dose varied widely among the studies included in those reviews. 
However, in those reviews morphine consistently reduces pain scores, increases time to 
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first analgesic dose after operation, and reduces postoperative opioid requirements. 
Morphine was unable to attenuate the stress response induced by cardiac surgery and CPB. 
However, in contrast to IT morphine, there is encouraging data to suggest that high spinal 
analgesia (with local anesthetics) reduces the stress response and β-receptor dysfunction 
after cardiac surgery with CPB in both adult and pediatric patients (Lee et al. 2003, 
Humphreys et al. 2005). In a study of 38 adult patients undergoing CABG surgery, IT 
analgesia (5 ml of 0.75% hyperbaric bupivacaine) was injected into the L2-4 interspace and 
patients were positioned in the Trendelenburg position (Lee et al. 2003). At least T1-level 
spinal anesthesia with cold sensation testing was confirmed in all included patients. 
Patients in the IT anesthesia group had CPB times over 1 h and exhibited no signs of 
impaired β-receptor density or function compared with the control group, in which β-
receptor function was significantly suppressed and receptor density also declined by 20%. 
Postoperative plasma catecholamines were significantly lower in the IT group than in 
controls; however, VAS scores and spirometry values were not improved in patients who 
received postoperative morphine administration compared with control patients. 
The meta-analysis (Meylan et al. 2009) found that IT morphine decreased postoperative 
opioid requirements after cardio-thoracic surgery by 9.7 mg (95% CI -17.6 -1.80); median 
postoperative 24-h morphine consumption in the control group was 34.5 mg. In the IT 
group, median morphine consumption was reduced less on the second postoperative day 
than during the first 24 h, by a mean value of 6.5 mg (95% CI 10-3 mg). 
Pain intensity at rest was reduced by 2 cm on the 10-cm VAS scale up to 4 h after 
surgery and by 1 cm at 12 and 24 postoperative hours. Pain intensity on movement was 
reduced by 2 cm at 12 and 24 postoperative hours. Unfortunately, improved analgesia was 
achieved at the expense of increased adverse effects. Respiratory depression (OR 8; 95% CI 
1.5-40) and pruritus (OR 4; 95% CI 2-6) were increased with IT morphine administration. 
Contrary to earlier studies of intrathecal morphine, a study by Zarate et al. indicated 
that extubation may not be prolonged and respiratory depression may be less likely to 
occur when anesthetics are chosen carefully (Zarate et al. 2000). In that study, remifentanil 
was combined with desflurane and IT morphine was administered preoperatively as an 8 
µg/kg bolus; the control group received sufentanil-based anesthesia. Postoperative opioid 
analgesic use was reduced 80% at 24 h and VAS scores were significantly reduced during 
the entire 24-h study period. Notably, tracheal extubation was not prolonged in the IT 
morphine group. However, respiratory depression after IT morphine remains a significant 
safety concern, and the technique is not widely popular. 
2.8.2.2 Epidural analgesia 
The use of epidural analgesia in cardiac surgery has been evaluated in numerous studies, 
clinical reviews, and meta-analyses. The potential benefits and associated risks of thoracic 
epidural analgesia remain controversial. In addition to improved analgesia, the potential 
benefits of epidural analgesia in cardiac surgery involve attenuated stress response, 
thoracic cardiac sympathectomy, improved coronary blood flow with increased myocardial 
oxygen supply, decreased myocardial ischemia, diminished arrhythmia, decreased 
intubation time, and fewer pulmonary complications (Chaney. 2006).  
In 2001, only 7% of anesthesiologists used epidural techniques in adult cardiac surgery 
according to a survey; however, its use has since increased (Goldstein et al. 2001). The fear 
of epidural hematoma associated with heparin anticoagulation has limited widespread use 
of epidural analgesia in cardiac surgery. The risk of epidural hematoma was estimated by 
Ho et al. to be from 1:150 000 to 1:1500 (95% CI) for epidural blockade before there were any 
reports of real epidural hematoma in cardiac surgery patients (Ho et al. 2000). Since then, 
there have been several reports of epidural hematoma in cardiac surgery or attempted 
cardiac surgery with or without epidural catheter insertion (Sharma et al. 2004, Ruppen et 
al. 2006, Rosen et al. 2004, Hemmerling et al. 2004, Cultrera et al. 2004). Although the 
incidence of epidural hematoma is rare, the potential consequences are serious. The true 
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risk and incidence are difficult to estimate. Therefore, the potential risk-benefit ratio for 
epidural block should be considered individually, as suggested lately in the Nordic 
guidelines for neuraxial block in disturbed hemostasis (Breivik et al. 2010).  
The clinical benefits of TEA in cardiac surgery were first evaluated in a large-scale study 
in 2001 (Scott et al. 2001). In that (unblinded) study, bupivacaine and clonidine were 
administered via TEA catheters inserted immediately before cardiac surgery. The control 
group received target controlled alfentanil i.v. infusion during the first postoperative 24 h, 
followed by PCA with i.v. morphine. The results of the study, which included 408 analyzed 
patients, showed reduced incidence of supraventricular arrhythmias, less postoperative 
confusion, and fewer cases of respiratory tract infections or renal failure in the TEA group 
(Scott et al. 2001). Patients in the TEA group were also extubated earlier. The study has 
since been criticized for a number of reasons: the study groups were unequal; clonidine 
infusion was used; postoperative β-blockade use was excluded; and hemodynamics, pain 
values, and length of hospital stay (LOS) were not reported. Since the Scott study was 
conducted, several relatively large studies have observed reduced time to tracheal 
extubation and improved postoperative analgesia in patients with TEA. No other 
advantages were obtained. In a 2004 meta-analysis, Liu et al. reported reduced risk of 
dysrhythmias and pulmonary complications (pneumonia, atelectasis), as well as better pain 
relief at rest and with activity (Liu et al. 2004). The latest (and thus far the largest) 
randomized study, by Svircevic et al., included 654 patients in elective cardiac surgery with 
follow-up at 30 days and 1 year after surgery (Svircevic et al. 2011a). Fast-track anesthesia 
included remifentanil, propofol infusion, or sevoflurane aiming at bi-spectral index (BIS) 
values between 40 and 60. That study was unable to demonstrate any clinical benefit 
regarding major complications in TEA compared with the control group (morphine 
infusion administered for postoperative analgesia). The same research group also 
accomplished a meta-analysis of 28 studies, which included more than 2,700 patients. A 
reduction of respiratory complications and supraventricular arrhythmias was observed in 
the thoracic epidural group, with risk ratios of 0.53 (95% CI 0.40 – 0.69) and 0.68 (95% CI 
0.50 – 0.93), respectively (Svircevic et al. 2011b). In contrast to previous data, a recent study 
by Caputo et al. observed reduced length of postoperative hospital stay (5 vs. 6 days, HR 
1.39, 95% CI 1.06 – 1.82) after off-pump cardiac surgery in the TEA group (Caputo et al. 
2011). The incidence of arrhythmias and median intubation time were also reduced in the 
TEA group in that study compared with the control group, in which morphine PCA was 
utilized for postoperative analgesia. 
Altogether, it appears that no major clinical benefits have thus far been achieved with 
TEA techniques, and the risk of epidural hematoma and paraplegia, although small, 
appears to be real and has already been substantiated in many centers. Therefore, the 
potential benefits of TEA in cardiac surgery may not justify the potential risks, at least in 
conventional cardiac surgery with full heparinization and CPB (Svircevic et al. 2011a, 
Svircevic et al. 2011b). 
2.8.2.3 Paravertebral analgesia 
Thoracic paravertebral block is a technique of administering local anesthetic solution 
adjacent to thoracic vertebrae, near the site where spinal nerves emerge from the 
intervertebral foramina (Karmakar. 2001). Various techniques for performing thoracic 
paravertebral block have been described and different local anesthetics have been utilized 
(Richardson et al. 2011). This blockade can be delivered as a single- or multiple-site 
injection and uni- or bilaterally, and also as a continuous infusion utilizing a catheter. It has 
been used in thoracotomy, as well as after sternotomy in cardiac surgery (Carmona et al. 
2011). The advantages of thoracic paravertebral compared with epidural blockade in 
cardiac surgery are relatively easy injection and less risk of serious neurological 
complications (epidural hematoma, paraplegia) following anticoagulation. Recently, 
interest in this old technique has been renewed, with descriptions of ultrasound or nerve 
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stimulation in the anterior paravertebral space (Karmakar et al. 2009). However, there are 
only a few comparative randomized studies of thoracic paravertebral block in patients 
undergoing sternotomy or lateral thoracotomy during MIDCAB surgery. In Dhole´s study 
of 41 MIDCAB patients, analgesia and the need for supplemental analgesics were similar 
compared with epidural analgesia during the first 12 postoperative hours (Dhole et al. 
2001). No complications were detected, but the sample size was small. Olivier compared 
bilateral single shot thoracic paravertebral blockade with TEA in median sternotomy 
patients. In that 52-patient study, postoperative pain scores were consistently lower in the 
TEA group during the first 24 postoperative hours (Olivier et al. 2007). Notably, all patients 
were extubated immediately after surgery. Thoracic paravertebral block may thus be a 
useful alternative, especially if a minimally invasive approach or thoracotomy incision is 
employed during cardiac surgery, i.e., in thoracotomy (MIDCAB) or transcatheteric aortic 
valvuloplasty procedures (TAVI). 
2.8.2.4 Local wound analgesia 
Continuous local wound infiltration is an attractive method to treat post-sternotomy pain 
after cardiac surgery. Local anesthetics are devoid of opioid-related adverse effects, namely 
respiratory depression, drowsiness, sedation, and nausea and vomiting. On the other hand, 
local anesthetics can be administered with specifically manufactured catheters to the site of 
surgical trauma (e.g., the sternotomy wound in cardiac surgery), and risks associated with 
central neuraxial techniques, epidural/spinal hematoma, and systemic hypotension could 
be avoided (Liu SS 1996, White et al. 2003, Dowling et al. 2003, Kocabas et al. 2008). 
At the moment, there are few studies using local infusion analgesia in cardiac surgery 
and the results are somewhat contradictory. White et al. studied continuous 2.5 mg/mL and 
5 mg/mL bupivacaine in a placebo-controlled trial in 36 patients assigned to open heart 
surgery. Bupivacaine was administered as a continuous infusion (4 mL/h) with an 
elastomeric infusion pump through two catheters placed at the median sternotomy site at 
the end of surgery (White et al. 2003). The authors observed lower VRS pain scores and 
PCA morphine requirements in patients treated with 5 mg/mL bupivacaine compared with 
the placebo group, but not in patients treated with 2.5 mg/mL bupivacaine compared with 
the placebo group. In addition, the duration of hospital stay was shorter in the bupivacaine 
5 mg/mL group than in the placebo group (4.2 vs. 5.7 days). The bupivacaine serum 
concentrations remained below the presumed toxic concentration of 4 µg/mL at the end of 
the 48-h study period in both groups. One catheter tip was inadvertently broken and had to 
be removed with a re-explorative operation. Investigators reported catheter-related 
problems (inadvertent removal or breakage of the catheter) in 13% of cases. Unfortunately, 
the small number of included patients limits the conclusions of other outcome variables. 
Similarly, in Dowling's study 35 CABG patients received a 48-h infusion of ropivacaine or 
saline with an elastomeric pump and two infusion catheters directly over the sternum 
(Dowling et al. 2003). Postoperative analgesics were administered via PCA as in White's 
study. Ropivacaine was administered as bilateral 20 ml 2mg/mL intercostal (T1 – T12) nerve 
injections, and continued thereafter with 4 mL/h of 2 mg/mL ropivacaine infusions over the 
sternum. They observed that the total narcotic analgesia (morphine or meperidine) 
requirements were significantly less in the ropivacaine-treated group than in the saline 
group (47 vs. 79 mg). Mean pain scores were also reduced in the ropivacaine-treated group 
compared with the saline group (1.6 vs. 2.6, on a VAS scale from 0 to 10). The mean LOS 
was shorter (5.2 vs. 6.3 days) in the ropivacaine-treated group than in the saline group. 
As opposed to previous studies, Magnano et al. observed no difference in postoperative 
pain or postoperative morphine administration in 47 cardiac surgery patients receiving 10 
mL of 5 mg/mL bupivacaine wound infiltration followed by continuous infusion of 120 
ml/24 h for 36 h postoperatively compared with control without local anesthetics (Magnano 
et al. 2005). The difference between the previous studies and Magnano’s study was the use 
of an epidural catheter with a few holes only at the tip of the catheter, instead of specifically 
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manufactured catheters with multiple holes utilized in the two positive studies described 
above. 
One study has investigated the infiltration of a single dose of 60 ml 2.5 mg/mL 
levobupivacaine at the sternotomy and the mediastinal tube sites at the end of surgery 
(Kocabas et al. 2008). Postoperative morphine consumption was significantly less (30 vs. 43 
mg, respectively) in the levobupivacaine group than in the placebo group, although VAS 
scores did not differ between groups. During the immediate postoperative period (4 h 
postoperatively), sedation scores were higher in the control group than in the 
levobupivacaine group. 
Local anesthetic infusion appears to be a promising technique to reduce opioid-related 
adverse effects; it may be insufficient by itself, but useful when combined with other 
methods. However, larger-scale studies are needed to clarify the true efficacy, safety, and 
optimal dosing of local anesthetics in the future. 
2.8.3 Other methods 
Aside from analgesics in the form of pharmaceutical preparations, various methods have 
been investigated to find methods that alleviate pain without adverse effects. Watt-Watson 
investigated the impact of preoperative education in the form of an educational booklet that 
informed the patient about the importance of proper pain relief, pain relief methods, 
individual responses to pain, concerns that stop patients from taking analgesics, and how to 
ask for help with pain. They included a rather large cohort of patients in a prospective 
manner: 406 patients divided into standard care or standard care and booklet groups. No 
effect on pain management was observed (Watt-Watson et al. 2004). Notably, one-third of 
patients did not remember the booklet at all. The information given had no effect on pain 
therapy, analgesic use, or patients’ consideration of taking medication. In that study, a large 
number of patients reported severe pain: 50% reported severe pain on movement on day 2 
and 30% of patients did so on day 5. 
Massage therapy has also been described as a beneficial postoperative intervention for 
cardiac surgery patients. Massage therapy has been suggested to reduce pain and pain-
associated tension and anxiety. Massaging is thought to alleviate pain through inhibition in 
the spinal cord, by creating impulses that inhibit pain-propagating pathways at the level of 
inhibitory interneurons. Activation of the parasympathetic system and psychological 
benefits are also reported benefits of massage therapy. However, thus far, there are only 
case reports and a description of the method used (Anderson and Cutshall. 2007). No real 
controlled studies have been described. 
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3 Aims of the Study  
The objective of the current study was to investigate the incidence and characteristics of 
acute and persistent postoperative pain, to test opioid adjuncts in alleviating pain after 
cardiac surgery, and to test whether dosing of short-acting opioid during surgery affects 
postoperative pain and the requirement for analgesics after surgery. 
 
Specifically, the aims were to: 
 
1) Study the incidence and intensity of acute postoperative pain and patients’ 
expectations before operation and their experiences after CABG-surgery. 
2) Study the incidence, intensity, and time course of persistent postoperative pain after 
CABG surgery. 
3) Test the opioid-sparing effect and efficacy of propacetamol to alleviate postoperative 
pain after CABG surgery. 
4) Evaluate the efficacy and feasibility of S-ketamine as an analgesic adjunct after 
CABG surgery. 
5) Investigate whether a high-dose remifentanil infusion induces opioid tolerance, 
measured as increased opioid consumption and postoperative pain after CABG. 
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4 Patients and Methods 
4.1 PATIENTS 
Altogether, this thesis comprises four studies including 472 patients. All patients 
underwent CABG surgery and were treated in the Kuopio University Hospital operating 
rooms (OR), post-anesthesia care unit (PACU), and cardiothoracic surgery ward. 
 
Table 3. Patient baseline characteristics, cardiac surgery, and study inclusion criteria.  
 
 Study I Study II Study III Study IV 
Study design 
Prospective cohort Randomized 
double-blind 
Randomized 
double-blind 
Randomized 
double-blind 
Inclusion criteria 
CABG, Age < 70 years CABG, Age < 70 
years 
CABG, Age < 70 
years 
CABG, Age < 70 
years 
Evaluated patients (n) 231 88 102 100 
Randomized patients (n) *213/221/205/198/204 79 90 90 
Sex (M/F) 176/37 69/10 80/10 75/15 
Age, mean (years) 59 58 57 57 
Opioid used during 
anesthesia 
fentanyl or sufentanil fentanyl + 
alfentanil 
fentanyl + 
alfentanil 
remifentanil 
 
* Numbers  correspond  to  patients  at  baseline/4  days  after/3 months  after/6 months  after/12 
months after surgery. 
 
4.2 METHODS 
All studies were approved by the ethics committee of Kuopio University hospital and were 
conducted according to the Declaration of Helsinki, and the Finnish Medicines Agency was 
notified. All patients were informed about the voluntary nature of the studies and all 
provided written informed consent. 
Randomization into treatment groups in studies II, III, and IV was accomplished by an 
independent statistician using random numbers and a balanced design with a computer-
generated table. Our hospital pharmacy prepared sealed envelopes including the patient 
number and study treatment group according to the randomization. The propacetamol and 
placebo ampoules for study II were provided by a pharmaceutical corporation (see below). 
The study medication syringes for studies III and IV were prepared by a nurse anesthetist 
not otherwise involved in the study or treatment of the patients. 
Study I was a prospective questionnaire study. Patients received questionnaires on the 
preoperative day, and at 4 days and 3, 6, and 12 months postoperatively by mail. 
Questionnaires were to be returned in a prepaid envelope. 
Studies II and III were randomized, placebo-controlled double-blinded investigations of 
opioid analgesic adjuvants of propacetamol and ketamine, respectively. In study IV, two 
remifentanil doses (0.1 µg/kg/min and 0.3 µg/kg/min) were infused during CABG surgery 
in a randomized, double-blind fashion. 
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All patients enrolled were younger than 70 years of age. Exclusion criteria included 
sleep apnea syndrome, hepatic or renal dysfunction in study II, patients with low cardiac 
output (< 2.0 l/m2/min), and prolonged weaning from the ventilator (>12 h). Patients who 
underwent heart valve or OPCAB surgery were excluded from studies II, III, and IV, as 
were patients who were unable to use a PCA pump. Patients with a psychiatric diagnosis 
and those who had medication for mental illness and alcohol or drug abuse were excluded 
from study III. 
4.2.1 Anesthesia 
A standardized anesthesia protocol was used for all patients in studies II, III, and IV. In 
study I an anesthetic protocol routinely used in our anesthetic department in cardiac 
surgery operations was implemented. 
In studies II, III, and IV, anesthesia was standardized according to study protocol. In 
studies II and III, anesthesia was induced with a bolus of 0.1 mg midazolam, 15 µg/kg 
fentanyl, 1 mg/kg propofol, and 0.1-0.15 mg/kg pancuronium, and maintained with 
propofol infusion at 2-3 mg/kg/h and alfentanil infusion at 50 µg/kg/h; an additional 1-2.5 
mg bolus was administered if analgesia was considered insufficient. Isoflurane 
supplementation was utilized at the discretion of the anesthesiologist in charge. In study 
IV, all patients received 2 µg/kg sufentanil before surgical incision; propofol bolus and 
maintenance of anesthesia were similar to studies II and III, with propofol and isoflurane 
administered as needed. A sufentanil bolus (50 µg) was allowed if analgesia was deemed 
unsatisfactory during surgery. In contrast to studies II and III, in study IV remifentanil was 
administered as a 0.3 µg/kg/min infusion in the treatment group instead of alfentanil, 
resulting in a total dose of 4.2 ± 1.1 mg of remifentanil per patient. An identically appearing 
placebo with the same infusion rate was administered to the control group. 
4.2.2. Outcome measurements 
Pain was assessed using a 10-cm VAS scale (0 = no pain, 10 = most pain imaginable) (studies 
II and III); a 100-mm VAS scale (study IV); or on an 11-point numeric rating scale, NRS (0 = 
no pain, 10 = most pain imaginable) (Study IV). All pain measurements were accomplished 
at rest and during a deep breath. 
Pain relief and overall satisfaction with analgesia was measured using the NRS scale, 
with a score of 0-3 indicating poor pain relief and dissatisfaction, 4-6 indicating moderate 
relief and satisfaction, and 7-10 indicating good pain relief and satisfaction with analgesia 
(study IV). 
Overall satisfaction with pain therapy was assessed using a 4-point scale: 1 = very 
satisfied, 2 = satisfied, 3 = unsatisfied, 4 = very unsatisfied (studies II, III and IV). Sedation 
was estimated in the PACU using a 7-point sedation-agitation scale (SAS) (from 0 = 
unarousable to 6 = combative) or a Ramsay score (from 1 = anxious and agitated to 6 = no 
response); in the surgical ward, the 10-cm VAS scale (0 = no sedation, 10 = most sedated 
imaginable) was used. 
In study III, success of mobilization on the second postoperative morning was assessed 
by the physiotherapist using a 5-point scale. Each step was scored from 0 to 2, with 0 points 
= not able to do the step, 1 point = a step accomplished with little help, and 2 points = 
success without any help. The five steps were 1) moving from supine to sitting position, 2) 
moving to the side of the bed, 3) getting up beside the bed, 4) walking, and 5) lying down 
on the bed. The physiotherapist also evaluated pain associated with walking by using a 10-
cm VAS score. Patients were also asked if they would choose the same pain control method 
if they had the operation a second time. 
Pulmonary function test, forced vital capacity (FVC), forced expiratory volume in 1 sec 
(FEV1), and peak expiratory flow rate (PEF) were tested in studies II and III with a portable 
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pulmonary function monitor (Vitalograph Escort, Buckingham, England). The monitor was 
calibrated before each measurement as indicated according to the manufacturer. Each 
measurement was duplicated and the best value was recorded. Arterial blood gas samples 
were taken in studies II and III on the first three and two postoperative mornings, 
respectively, and analyzed immediately (ABL-520, Radiometer, Copenhagen, Denmark). 
In study III, oxygen consumption (VO2) and carbon dioxide production (VCO2) were 
measured with indirect calorimetry before surgery (canopy mode), before extubation 
(ventilator mode), and on the first postoperative morning (canopy mode) (Deltatrac, Datex-
Ohmeda, Helsinki, Finland) for 20 min; the first 5 min were disregarded and values were 
averaged. The monitor was calibrated before measurement according to the manufacturer’s 
instructions. 
In study III, cognitive function was evaluated with the Mini-Mental State Examination 
(MMSE) (Folstein MF et al.), which is rated from 0 to 30, and with the Delirium Rating Scale 
(DRS) (Treapcz PT et al.), which is rated from 0 to 32 points. Both were recorded by the 
study nurse guided by a neuropsychologist. The study patients were also asked if they 
experienced hallucinations or unreal perceptions during the study period. 
Surgical operations consisted of a standard midline sternotomy, with harvesting of 
saphenous vein and internal mammary artery as indicated. The heart was arrested in 
asystole during aortic occlusion with antegrade intermittent crystalloid cardioplegia, and 
patients were cooled to 34°C and rewarmed to 37°C before release of the aortic occlusion. 
CPB was conducted by membrane oxygenation. 
4.2.3 Analgesic adjuncts 
4.2.3.1 Propacetamol, Study II 
The propacetamol (UPSA, Agen, France) and placebo ampoules manufactured and 
provided by the UPSA pharmaceutical company for study II were identical in packaging 
and appearance. The blinding and procedure were performed in our hospital pharmacy 
according to the randomization protocol. Propacetamol was administered as 2 g of 
propacetamol hydrochloride at 6-h intervals (4 times daily) in 100 ml of normal saline, or a 
placebo in 100 ml of normal saline. All patients received 12 doses of propacetamol or 
placebo. 
4.2.3.2 S(+)‐ketamine, Study III 
In study III, S(+)-ketamine (Ketanest-S, Pfizer, Espoo, Finland) was administered as 75 
µg/kg in 15 ml of saline, administered as a 15-min bolus started immediately after 
anesthetic induction and thereafter as 1.25 µg/kg/min for 48 h after arrival to PACU. The 
S(+)-ketamine or placebo infusion was prepared by a nurse anesthetist who was not 
involved in patient evaluation or patient care according to the randomization protocol. The 
sealed envelope technique was utilized to indicate patient group; each envelope was 
opened just before preparation of the infusion on the operative morning. The syringes used 
to administer each study drug or placebo infusion were identical in appearance. 
4.2.3.3 Remifentanil (during surgery), Study IV 
Remifentanil was administered as a continuous infusion at 0.3 µg/kg/min. Remifentanil and 
placebo infusions were begun immediately after anesthesia induction and were continued 
until the end of surgery. Each infusion was prepared as in study III. 
4.2.4 Postoperative analgesia 
After extubation, patients had access to i.v. oxycodone with a PCA device (Graseby 3300P, 
Hoyer, Bremen, Germany). The PCA protocol was standardized as follows for studies II 
and III: bolus dose 2 mg, dose duration 2 min, lockout interval 13 min (15-min effective 
lock-out time); no background infusion or upper dose limit. In study IV, the PCA protocol 
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was standardized as follows: bolus dose 1 mg, dose duration one min, lock-out interval 5 
min (6-min effective lock-out time), with no background infusion or upper dose limit. In 
addition to oxycodone administered from a PCA device, an extra bolus dose of oxycodone 
(5 mg i.v.) was allowed both before and after extubation if pain relief with PCA was 
assessed as insufficient. In study IV, an opioid titration was applied to control pain after 
extubation and before commencing PCA. Oxycodone was administered as 2 mg boluses i.v. 
every 10 min until VAS score at rest was ≤ 3 or excessive sedation (SAS < 4) or respiratory 
depression occurred (respiratory rate ≤ 8/min). Total oxycodone consumption was recorded 
from the PCA device at the end of the study, and combined with doses adminstered as 
rescue analgesics or during opioid titration in study IV. 
4.2.5 Statistical methods 
In study I, no formal sample size calculation was performed. However, a sample of 200 
CABG patients was estimated to be sufficient because an incidence of 28% persistent 
postoperative pain was reported for this patient group. Assuming a 15% dropout rate, 231 
patients were included. 
In study II, sample size estimation was based on a previous study by Boldt et al. (Boldt 
et al. 1998). The variability of postoperative analgesic requirement among individual 
patients was estimated from the Boldt study and from a small pilot sample from our 
department. When postoperative opioid consumption was assumed to decrease 30% with a 
study medication, using a two-sided α of 0.05 and power of 80%, the power analysis 
indicated that a total of 70 patients would be needed. We assumed a 20% dropout rate and 
included 88 patients in the study. 
The sample size calculations in studies II and IV were based on the average opioid dose 
(mean 141.8, SD 57.5 mg) administered to the placebo group in study II. However, based on 
the possibility that the sample size in study II might have been too small, larger sample 
sizes (including 90 patients) were enrolled in studies III and IV. 
Patient characteristics and anesthetic and operative variables were compared using 
Student’s t-test for independent samples (continuous variables), or the Mann-Whitney U-
test and χ2-test (Pearson) or Fisher’s exact test when appropriate (categorical variables). 
In study I, the association of various risk factors with persistent pain was tested with 
Fisher’s exact test. Comparison of pain scores over time was performed using Friedman, 
and multiple comparisons of consecutive persistent pain scores were made using the 
Wilcoxon signed rank test. 
Cumulative oxycodone consumption between groups was compared using Student’s t-
test for independent samples after tests for homoscedasticity (equality of variances) and 
normality (in studies II and II), or with the Mann-Whitney U-test for independent samples 
(in study IV). VAS scores were compared over time using two-way analysis of variance for 
repeated measurements by using a mixed design. A two-sided p-value <0.05 was 
considered statistically significant. Results are provided as mean (SD) or number of 
patients, as appropriate. All statistical analyses were performed using SPSS software (SPSS 
Inc., Chicago, IL, USA). 
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5 Results 
5.1 PREOPERATIVE EXPECTATIONS OF ACUTE POSTOPERATIVE PAIN 
AFTER CABG SURGERY 
The pain that patients were willing to accept after cardiac surgery without pain relief at rest 
was mild, median VAS 3 (range 0-8), and only slightly higher during coughing and on 
movement, median VAS 4 (range 0-10) (Figure 3). The median pain relief patients wished 
from pain medication was 9 (0-10), on the NRS scale from 0 to 10. During the preoperative 
inquiry, only 45 (21%) of all patients wanted total postoperative pain relief (i.e., no pain at 
all after medication). The majority of patients (60%) were unaware of the possible adverse 
effects of pain medication, and only 3% and 2% believed that their medication would 
induce nausea and vomiting, respectively. 
  Figure 3 The proportion of patients who were willing to accept no (NRS = 0), mild (NRS = 1-
3), moderate (NRS = 4-6), or severe (NRS = 7-10) pain, scored on an 11-point NRS scale 
after CABG surgery (preoperative questionnaire).  
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5.2 ACUTE POSTOPERATIVE PAIN AFTER CABG SURGERY 
The pain that patients actually experienced after surgery was more intense than they were 
willing to accept (p < 0.001), and more intense than they expected (p = 0.013; Table 4). The 
worst actual postoperative pain was 6 (0-10) at rest, 7 (0-10) on movement, and 8 (2-10) 
during coughing. On POD 4, pain had been reduced to mostly mild at rest and during 
movement; however, it remained moderate or severe during coughing (Figure 4). On POD 
4, 160 (75%) of patients had chest pain, 40 (19%) had leg pain, 29 (14) had shoulder pain, 
and 20 (9%) had back pain. 
 
     
 
31
Figure 4. Incidence of acute postoperative pain on an 11-point NRS scale after CABG surgery.  
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Figure 4. Incidence of acute postoperative pain on an 11-point NRS scale after CABG surgery.  
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Figure 4. Incidence of acute postoperative pain on an 11-point NRS scale after CABG surgery.  
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5.3 PERSISTENT POSTOPERATIVE PAIN AFTER CABG SURGERY 
The response rates for pain questionnaires from patients that completed the first 
questionnaire (213 patients) were 95% (203), 88% (187), 85% (180), and 87% (186) after 1, 3, 
6, and 12 months, respectively. 
Postoperative persistent pain from 1 to 12 months was common, and was seldom 
considered severe after CABG surgery. After one month, the reported pain values were 
mostly mild, although individual variation remained substantial (Table 4). One year after 
surgery, mild persistent post-sternotomy pain at rest was frequent in 26 patients (14%). One 
patient (1%) had moderate pain and 3 patients (2%) had severe pain. On movement, 
persistent pain was more common at one year: 45 patients (24%) reported mild, 5 patients 
(3%) reported moderate, and 7 patients (4%) reported severe pain. Chest pain was 
described as burning in 12%, tender in 59%, and numbness in 30% of cases. 
 
Table 4. Postoperative pain intensity at rest in CABG patients.  
 
Time 
No pain  
0 
Mild 
1-3 
Moderate 
4-6 
Severe 
7-10 
Postoperatively (first 24 h) (n = 213) 8 (4) 66 (31) 83 (39) 55 (26) 
4th postoperative day (n = 213) 56 (26) 105 (49) 38 (18) 14 (7) 
1 month (n = 203) 83 (41) 106 (53) 10 (5) 2 (1) 
3 months (n = 187) 119 (65) 59 (31) 5 (3) 1 (1) 
6 months (n= 180) 139 (78) 35 (20) 1 (1) 1 (1) 
12 months (n = 186) 154 (84) 26 (14) 1 (1) 3 (2) 
Number of patients, n (%). 
At 3 months 27 (14%) patients, at 6 months 21 (12%) patients, and at 12 months 18 (10%) 
patients reported that pain had disturbed their normal nightly sleep. Patients who reported 
moderate to severe acute postoperative pain (NRS > 3) were more likely to have persistent 
pain (NRS 1-10) at rest 1 year after the operation (p = 0.042) than patients who reported 
mild acute pain.  
5.4 PROPACETAMOL AS ADJUNCTIVE TREATMENT FOR POSTOPERATIVE 
PAIN AFTER CABG SURGERY 
There was no significant difference in postoperative cumulative oxycodone consumption 
between the propacetamol-treated group and the placebo group (mean difference 18.3 mg, 
95% CI 6.1 - 42.7 mg; p = 0.15). However, in a post hoc analysis after completion of the 
study, the cumulative opioid consumption during the first 24 h was lower in the 
propacetamol group than in the placebo group (p = 0.036, Table 5). 
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Table 5. Postoperative oxycodone requirements in the propacetamol-treated group and the 
placebo group after CABG surgery.* Post hoc analysis; values represent mean ± SD.  
 
 
Placebo (n = 39) Propacetamol (n = 40) p-
value 
Oxycodone total (mg) 141.8 ± 57.5 123.5 ± 51.3 0.15 
Rescue oxycodone* (mg) 6.0 ± 4.9 5.1 ± 4.7 0.39 
Number of patients who received rescue oxycodone (n) 30 27 0.35 
Oxycodone in 24 h* (mg) 57.9 ± 23.9 47.1 ± 20.7 0.036 
Oxycodone in 48 h* (mg) 108.5 ± 41.1 91.7 ± 38.2 0.065 
PCA oxycodone* (mg) 135.8 ± 56.1 118.4 ± 49.9 0.15 
 
VAS scores did not differ significantly between groups during the 66-h study period at 
rest (p = 0.65) or during a deep breath (p = 0.72). There was a drastic reduction in 
pulmonary function tests on the first postoperative day compared with preoperative 
values—PEF fell to 33% of the preoperative value and FEV1 and FVC decreased with 
similar magnitude, with no between-group differences. Pulmonary function values 
exhibited slow improvement on two subsequent postoperative days, and did not reach the 
preoperative level. The groups were also similar with respect to blood gas analyses, 
postoperative bleeding, hepatic function tests (ALT, γ-glutamyl transferase), and adverse 
events.  
Only one patient in the propacetamol group was excessively sedated. The median value 
was 2 (range, 5 during the operation and on the first postoperative day; range, 1 and 0 on 
the PODs 2 and 3, respectively) in both groups (Ramsey score from 1 to 6), with no 
difference between groups.  
5.5 S(+)-KETAMINE IN TREATMENT FOR POSTOPERATIVE PAIN AFTER 
CABG SURGERY 
During the first 48 postoperative hours, cumulative oxycodone consumption was less in the 
S(+)-ketamine group (103 ± 44 mg) than in the placebo group (125 ± 45 mg) (mean difference 
22 mg, 95% CI 3 - 40 mg; p = 0.023 (Fig. 5). The time to the first dose of oxycodone with PCA 
was longer in the S(+)-ketamine group (Table 6). 
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Table 6. Postoperative oxycodone requirements in the S(+)-ketamine and placebo groups after 
CABG surgery.* Post hoc analysis; data values represent mean ± SD.  
 
 Placebo (n = 46) S(+)-Ketamine (n = 44) p-value 
Oxycodone total (mg) 125 ± 45 103.5 ± 44 0.023 
Rescue oxycodone* (mg) 20.7 ± 16.9 12.9 ± 9.9 0.009 
 
Time to first PCA dose of oxycodone (min) 
101 ± 197 134 ± 125 0.013 
Oxycodone in 24 h* (mg) 65.8 ± 23.7 53.1 ±24.4 0.013 
Oxycodone in 48 h* (mg) 125 ± 45 103.5 ± 44 0.023 
PCA oxycodone* (mg) 104.0 ± 35.8 90.2 ± 38.0 0.081 
Opioid titration (oxycodone)* (mg) 3.8 ± 2.3 3.8 ± 3.7 0.988 
 
Pain scores did not differ between groups at rest (p = 0.17) or during deep breath (p = 
0.23) (Fig. 6). S(+)-ketaminetreated patients were more satisfied with the pain therapy than 
the placebo group. Twenty-six of 44 patients in the S(+)-ketamine group were very satisfied 
with the analgesic management, compared with 16 of 46 patients in the placebo group (p = 
0.032). Two patients in the placebo group were unsatisfied with the pain therapy, versus 
none in the S(+)-ketamine group. One patient was dissatisfied because of opioid-induced 
nausea, and the other was dissatisfied owing to unsatisfactory pain relief despite an 
excessive dose of oxycodone (220 mg). 
The groups were similar in terms of extubation time, pulmonary function tests, 
mobilization tests, walking exercise with physiotherapists, oxygen consumption (VO2), and 
carbon dioxide production (VCO2). Postoperative PaCO2 values were higher in the placebo 
group than in the S(+)-ketamine group (p = 0.021), although the difference was not clinically 
significant.  
There were no postoperative differences in cognitive function between the two groups. 
The mean value for MMSE (best outcome 30) was 23  2.6 in the S(+)-ketamine group and 
23  2.7 in the placebo group (p = 0.69), and the mean DRS value (from 0 to 32 points, best 
outcome 0) was 3.4  0.7 in the S(+)-ketamine group and 3.1  0.4 in the placebo group (p = 
0.10). However, in the DRS evaluation two patients in the S(+)-ketamine group achieved 
five points and one patient achieved six points, compared with no points achieved in the 
placebo group.  
Sedation scores did not differ between the groups: SAS scores on the operative day were 
3.6  0.1 in the S(+)-ketamine group and 3.7  0.1 in the placebo group (p = 0.735); VAS 
scores on the first POD were 3.3  0.2 in the S(+)-ketamine group and 3.4  0.2 in the 
placebo group (p = 0.115), and on the second POD were 3.4  0.2 in the S(+)-ketamine group 
and 2.9  0.4 in the placebo group (p = 0.140). 
Because four (8%) patients in the S(+)-ketamine group developed psychotomimetic 
disturbances (vs. none in the placebo group; p = 0.053 between the groups), discontinuation 
of the study drug infusion was considered. Two of these patients were very confused and 
were withdrawn from the study. The two remaining patients were offered the option to 
withdraw, but both decided to continue. In addition, all three pilot patients who received 
S(+)-ketamine as a 150 g/kg bolus and 2.5 g/kg/min infusion, a dosage based on previous 
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research (Adriaenssens et al. 1999), developed hallucinations. Hallucinations disappeared 
readily after S(+)-ketamine was discontinued in all of the affected patients. Remaining 
hospital care was uneventful for the remaining study patients. All patients with 
psychotomimetic adverse reactions recalled the event after the study period. Altogether, 
seven of 54 patients receiving ketamine developed major psychotomimetic adverse effects 
during S(+)-ketamine infusion, versus zero in the placebo group. 
A few adverse events occurred in both groups during or after the study period. Nausea 
and vomiting were the most common adverse events, with similar frequencies in the two 
groups (Table 7). 
 
Table 7. Postoperative adverse events in the S(+)-ketamine and placebo groups after CABG 
surgery .Values represent the number of patients.  
 
 Placebo (n = 46) S (+)-Ketamine (n = 44) p-value 
Nausea 13 18 0.27 
Vomiting 7 11 0.30 
Psychotomimetic adverse reactions 0 4 0.053 
Excessive sedation 0 2 0.49 
Postoperative hypotension 2 0 0.49 
 
 
Figure 5. Cumulative oxycodone consumption in the S(+)-ketamine and placebo groups after 
CABG surgery (p = 0.023 at 48 h after surgery). 
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Figure 6. VAS scores at rest and during deep breath in the S(+)-ketamine and placebo groups 
after CABG surgery. Values represent mean ± SD. OD-EXT, operation day, immediately after 
extubation and before commencing PCA on the operation day; OD-TITR, operation day, after 
titration of oxycodone until VAS score was ≤ 3 on the operation day; ODPCA-24H, after having 
access to PCA at 1200 on the operation day; POD1-8H, at 0800 on the first postoperative day; 
POD1-16H, at 1600 on the first postoperative day; POD1-24H, at 1200 on the first 
postoperative day; POD2-8H, at 0800 on the second postoperative day; POD2-16H,at 1600 on 
the second postoperative day.  
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5.6 POSTOPERATIVE PAIN AND OPIOID CONSUMPTION AFTER HIGH-
DOSE REMIFENTANIL INFUSION DURING CABG SURGERY 
Postoperative cumulative opioid consumption was similar between the remifentanil and 
placebo groups [remifentanil: median 99 (range 29 - 166); placebo: median 99 mg (range 42 - 
219); p = 0.603]. The VAS pain scores were comparable at rest (p = 0.372). However, patients 
in the placebo group had more pain during deep breath immediately after extubation and 
at 8 h and 16 h after extubation (p = 0.020, Fig.7).  
In study IV, sedation was assessed similarly to the assessment detailed in study III. The 
mean (SEM) SAS scores in the PACU on the operative day were 3.8 (0.1) in the remifentanil 
group and 3.8 (0.1) in the placebo group (p = 0.925). VAS scores in the surgical ward were 
3.8 (0.1) in the remifentanil group and 3.8  0.1 in the placebo group (p = 0.279) on the first 
POD, and 3.7 (0.1) in the remifentanil group and 3.7 (0.1) in the placebo group (p = 0.261) on 
the second POD. 
 
Table 7. Postoperative oxycodone requirements in the remifentanil and placebo groups after 
CABG surgery. *Post hoc analysis; values represent mean ± SD.  
 
 Placebo (n = 45) Remifentanil (n = 45) p-value 
Oxycodone total (mg) 104.8 ± 43.4 96.1 ± 29.4 0.269 
Rescue oxycodone* (mg) 4.0 ± 8.4 2.1 ± 4.5 0.225 
Time to first PCA dose of oxycodone* (min) 38.3 ± 51.5 50.5 ± 91.5 0.439 
Oxycodone in 24 h* (mg) 59.5 ± 27.9 54.7 ± 22.2 0.363 
Oxycodone in 48 h* (mg) 104.8 ± 43.4 96.1 ± 29.4 0.269 
PCA oxycodone* 84.5 ± 37.7 77.4 ± 26.9 0.311 
Opioid titration (oxycodone)* (mg) 4.3 ± 4.2 3.2 ± 3.0 0.281 
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Figure 7. VAS pain scores at rest and during deep breath in the remifentanil and placebo groups 
after CABG surgery. Values represent mean ±SEM. EXT, immediately after extubation and 
before commencing PCA on the operation day; TITR, after titration of oxycodone until VAS score 
was ≤ 3 on the operation day; 0, after having access to PCA at 1200 on the operation day; 8, at 
0800 on the first postoperative day; 16, at 1600 on the first postoperative day; 24, at 1200 on 
the first postoperative day; 32, at 0800 on the second postoperative day; 40, at 1600 on the 
second postoperative day. 
     
 
6 Discussion 
6.1 ACUTE AND PERSISTENT PAIN AFTER CABG SURGERY 
In study I, a prospective questionnaire study, patients were willing to accept only mild (at 
rest) or moderate (during coughing) postoperative pain. However, patients actually 
experienced more severe postoperative pain than they had expected preoperatively and 
indicated that they were willing to accept in the preoperative questionnaire. The actual 
average pain at rest after surgery was moderately intense, 5 on the VAS scale (0-10). The 
worst pain that patients experienced at rest during the first 24 postoperative hours was 
moderate in 39% and severe in 26% of patients after CABG surgery. Postoperative dynamic 
pain [i.e., pain during coughing (VAS 8/10) and on movement (VAS 7/10)] was severe in 
most patients. These results strikingly disagree with the common belief that post-
sternotomy pain is mild. The pain intensity reported in this study is more intense than the 
pain reported in other studies; the worst pain reported was 5/10 on VAS at rest, while the 
worst dynamic pain reported was 6/10 during mobilization (Gjeilo et al. 2007, Diby et al. 
2008, Mueller et al. 2000). Differences between the current study and previous studies may 
be explained by differences in questionnaire timing, patient populations, analgesia during 
surgery, and postoperative pain management.  
However, altogether these studies indicate that acute postoperative pain after cardiac 
surgery is located mainly in the chest (over the sternum), is moderate to severe in intensity 
during the first two postoperative days, and diminishes from day 3 onward. Additionally, 
the intensity of acute postoperative pain is unacceptably high, and more efficient pain relief 
methods should be implemented. The pain reported during the first 24 h in study I was 
more intense both at rest and during coughing or movement than the pain reported in 
studies III and IV. There may be methodological reasons for this discrepancy, given that 
dynamic pain may be more intense during coughing and movement than during a deep 
breath (Milgrom et al. 2004). However, incremental opioid titration to VAS ≤ 3 after 
extubation may have improved analgesia (at least at rest) in studies III and IV compared 
with standard practice in the PACU (i.v. oxycodone administered on demand), represented 
in study I. As indicated in the original publications, the VAS scores were also remarkably 
high in studies III and IV after extubation, decreasing below VAS 3 after opioid titration 
and then gradually increasing during PCA administration of oxycodone when patients 
titrated themselves to approximately VAS 3 at rest. However, during deep breath VAS 
scores were also considerably high in studies III and IV, at least VAS 5-6. Dynamic pain 
remains difficult to treat using patient self-administration of opioids.  
The opioid titration method employed after extubation in studies III and IV efficiently 
diminished the intensity of pain and should be considered as standard practice in the 
PACU. 
During the prospective follow-up period in study I, persistent postoperative pain was 
common during the first year after CABG. The incidence of persistent pain was 14% at 1 
year after surgery. The intensity of persistent pain was mostly mild at 6 and 12 months after 
surgery; however, 1% and 2% of the patients still experienced moderate to severe pain at 6 
and 12 months after surgery, respectively. This incidence is in aggreement with three other 
prospective studies, in which it varied widely between 11% and 28% at 1 year after surgery 
(Gjeilo et al. 2010, Meyerson et al. 2001, King et al. 2008); the incidence of severe pain has 
been more consistently quite rare (between 1% and 6%). There is no established evidence 
regarding which factors predispose an individual to persistent post-sternotomy pain. 
However, younger age, more severe acute postoperative pain, female sex, and ITA grafting 
have all been associated with persistent pain after cardiac surgery (Taillefer et al. 2006, 
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Gjeilo et al. 2010, Kalso et al. 1992, Meyerson et al. 2001, Nay et al. 1996, Perkins and Kehlet. 
2000, King et al. 2008). Persistent pain appears to be related to lower health-related QOL 
(HRQOL) compared with patients without pain, emphasizing the importance of this issue 
in health care (Taillefer et al. 2006, Gjeilo et al. 2010, Mäntyselka et al. 2003). This persistent 
pain syndrome, although rarely severe, also has implications regarding patient counseling 
with respect to early pain therapy in pain clinics or in public health.  
6.2 OPIOID ADJUNCTS PROPACETAMOL AND KETAMINE AFTER CABG 
SURGERY 
Propacetamol (administered as 2 g i.v. corresponding to 1 g of paracetamol), administered 
four times daily after CABG surgery, had no opioid-sparing effect during the first three 
postoperative days. However, in post hoc analysis when opioid consumption was split to 6-
h intervals, 24-h opioid consumption was reduced by 19% (a mean difference of 11 mg of 
oxycodone in 24 h) in the propacetamol group compared with the placebo group. No 
differences in postoperative pain were observed between groups. This opioid-sparing effect 
is unlikely to offer any significant clinical benefit for cardiac surgery patients. Although this 
result was unexpected, it is in agreement with findings from a large study of orthopedic, 
abdominal, and gynecological surgery patients in which propacetamol reduced opioid 
requirements less in patients with severe pain than in those with moderate pain (Aubrun et 
al. 2003). In that study, the reduction in morphine requirement was 18% in patients with 
severe pain, compared with 37% in patients with moderate pain. Similarly, a small 
significant decrease in postoperative morphine consumption with no reduction in opioid-
related adverse events was observed in two recent meta-analyses of paracetamol or 
propacetamol in the context of postoperative pain (Maund et al. 2011b, McDaid et al. 2010).  
The type of surgery may also be relevant to the efficacy of different analgesics. 
Paracetamol may be more beneficial regarding somatic than visceral pain, at least it appears 
to be more effective after orthopedic surgery than after soft tissue surgery (Hiller et al 2006, 
Sinatra et al 2005). Cardiac surgery is more complex than orthopedic procedures, and this 
difference in operations may have diminished the analgesic effect of propacetamol.  
Due to delayed gastric emptying and postoperative nausea and vomiting, paracetamol 
should be administered intravenously at least during the first two postoperative days 
(Berger et al. 2000, Schuitmaker et al. 1999) after cardiac surgery. The relatively high cost of 
i.v. paracetamol combined with its low efficacy regarding postoperative pain in the current 
study and other studies in cardiac surgery (Pettersson et al. 2005, Cattabriga et al. 2007) 
imply that it may not be the standard of care for postoperative pain after cardiac surgery.  
In study III, a small-dose S(+)-ketamine infusion as an adjunct to PCA oxycodone 
exerted a 17% opioid-sparing effect in the first 48 h after sternotomy in CABG patients. Pain 
scores were similar at rest and during deep breath in S(+)-ketamine and placebo groups. 
This opioid-sparing effect was relatively small and was not associated with any reduction 
in opioid-associated adverse effects. These results differ from the findings of several 
systematic reviews and meta-analyses in which ketamine exerted significant opioid-sparing 
and pain alleviating effects, and also reduced postoperative nausea and vomiting (PONV) 
(Subramaniam et al. 2004, Bell et al. 2006a, Laskowski et al. 2011). In comparison to the 
current study, the opioid-sparing effect in those reviews was consistently 16 mg in 24 
postoperative hours (Subramaniam et al. 2004, Bell et al. 2006b). In the most recent 
systematic review, the opioid-sparing effect was greatest in upper abdominal and thoracic 
procedures and authors concluded that the particular benefit of ketamine may be obtained 
in types of surgery that entail more intensive postoperative pain (> 70% of maximum pain 
score) (e.g., abdominal, thoracic, and orthopedic surgery) (Laskowski et al. 2011). There are 
no studies evaluating postoperative pain with ketamine administration in patients 
undergoing sternotomy. In an investigation of 58 MIDCAB/OPCAB or lung surgery 
patients, ketamine diminished morphine use by 50% (from 2 to 1 mg) of hourly morphine 
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consumption (Nesher et al. 2008). The total amount of morphine administered in the first 72 
postoperative hours was not reported. Pain scores were also significantly lower in the 
ketamine group than in the placebo group; however, the differences were not large, and 
there was no difference in PONV. The smaller opioid-sparing effect and lack of benefit 
regarding pain scores or adverse events in the current study compared with systematic 
reviews may be explained by more stressful surgery, postoperative administration of 
different analgesics (oxycodone vs. morphine), and limited sample size in the current 
study.  
Although the patients given S(+)-ketamine in this study were more satisfied with their 
pain therapy, a few developed psychological disturbances. These adverse events together 
with less than remarkable efficacy limit the popularity of S(+)-ketamine as an analgesic after 
cardiac surgery. Cognitive disorders are quite common after cardiac surgery, with a 22-53% 
incidence, and may substantially prolong hospital stay and increase morbidity (Taggart and 
Westaby 2001). In a recent study in elderly patients, delirium incidence was 23% and 58% of 
those with delirium also experienced hallucinations or illusions (Eriksson et al. 2002). 
However, recent studies indicate that ketamine may be neuroprotective, especially after 
cardiac surgery, with a proposed anti-inflammatory effect (Hudetz et al. 2009a, Hudetz and 
Pagel. 2010, Hudetz et al. 2009b, Welters et al. 2011). Ketamine may be useful in severe pain 
and in suppressing opioid tolerance and hyperalgesia as a part of balanced analgesia 
regime (Joly et al. 2005).  
The increased contentment with analgesia in the ketamine group compared with the 
placebo group may be explained by ketamine’s antideppressive effect. Ketamine posseses 
significant antidepressive effects (Kudoh et al. 2002, Barman et al.2000). The results of 
several small studies involving ketamine suggest that NMDA receptor antagonists may be 
effective in treating depression that is unresponsive to conventional antidepressants 
(Connolly et al.2012).  
6.3 REMIFENTANIL FOR PERIOPERATIVE ANALGESIA AND 
POSTOPERATIVE PAIN 
In study IV, remifentanil administered at 0.3 µg/kg/min during cardiac surgery did not 
increase postoperative oxycodone consumption, nor did it increase pain after surgery 
compared with placebo. Actually, pain scores were higher in the placebo group than in the 
remifentanil group after extubation and on the first postoperative day. These results 
indicate that remifentanil did not induce any opioid tolerance in CABG patients 
postoperatively. These findings are in agreement with a recent experimental study in 
human volunteers in which a 3-h target controlled remifentanil infusion corresponding to 
infusion rates of 0.65 and 1.3 µg/kg/min was administered (Angst et al. 2009). In that study, 
no detectable tolerance to analgesic, sedative, or respiratory opioid effects was observed. 
The authors suggested that total opioid exposure may explain the contradictory results of 
opioid tolerance during surgery, because in studies with 20-30 µg/kg of remifentanil there 
were no indications of opioid tolerance, while studies with 80-120 µg/kg of remifentanil 
indicated opioid-induced hyperalgesia. Relatedly, the average remifentanil dose in the 
current study was 51 µg/kg, which is between high and low dosing defined in the study of 
Angst et al. (Angst et al. 2009). The negative result in the current study may be due to lower 
total remifentanil dosing during surgery, or to a different anesthesia regime in our study 
compared with previous studies with indicating opioid-induced hyperalgesia (Guignard et 
al. 2000, Joly et al. 2005). In those investigations, desflurane inhalation was utilized instead 
of the propofol infusion administered as part of our anesthesia and postoperative sedation 
protocol. Remifentanil has been shown to induce a rapid and persistent increase in NMDA 
receptor response that may be one of the underlying mechanisms of increase in pain and 
opioid tolerance (Zhao and Joo. 2008,Orser et al. 1995). On the other hand, propofol inhibits 
the phosphorylation of NMDA receptor NR1 subunits in neurons at clinically relevant 
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concentrations (Kingston S et al. 2006). Even if the biological relevance of this inhibition of 
NMDA receptors is currently unclear, it may be the mechanism by which propofol 
attenuates remifentanil-induced hyperalgesia or tolerance (Singler et al. 2007). In clinical 
studies propofol has been shown to decrease postoperative pain and opioid requirements 
compared with sevo- or isoflurane (Shin et al. 2010, Cheng et al. 2008). Therefore, negative 
results in this study compared with the studies of Guignard et al. (Guignard et al. 2000) and 
Joly et al. (Joly et al. 2005), who observed a clinically significant increase in opioid 
consumption and postoperative pain after perioperative remifentanil, may be explained by 
discrepancies in anesthesia maintenance by propofol in our study versus desflurane in the 
studies of Guignard and Joly. After all, remifentanil-induced opioid tolerance or 
hyperalgesia appears to be avoidable with either low dosing of remifentanil (e.g., 0.5-1.3 
µg/kg/min) or co-administering propofol in anesthetic concentrations.  
6.4 LIMITATIONS OF THE STUDIES 
All of the patients included in this study were younger than 70 years of age, which may be 
a limitation in the generalizability of these results to the whole population of cardiac 
surgery patients, especially when the mean age of patients undergoing cardiac surgery is 
increasing. In fact, elderly patients (≥75 years of age) were shown to have less pain and 
decreased opioid requirements compared with middle-aged patients (65-74 years of age) 
(Pesonen et al. 2009). The aim in excluding older persons was to standardize patient 
populations in different studies included here, while minimizing the dropout rate due to 
the expected higher rate of perioperative complications in the elderly after surgery. The 
sample size in study II was too small to definitively detect a 30% decrease in opioid 
consumption between the propacetamol and placebo groups, possibly because variation in 
opioid consumption was greater than assumed. However, even if the reduction in opioid 
consumption had been larger, we observed no advantage of propacetamol regarding either 
improved pain scores or the adverse effects of opioids (PONV) in this study. In study IV, a 
relatively large dose of sufentanil was administered to the placebo group. This opioid 
dosing in the anesthesia induction may have induced opioid tolerance or hyperalgesia 
regardless of remifentanil and distorted the results. Therefore, the definitive answer to the 
question of whether high-dose remifentanil infusion increases opioid consumption and 
postoperative pain after cardiac surgery is still lacking. An additional study with high- and 
low-dose remifentanil without any other opioids is warranted in the future.  
Patients may remain moderately sedated postoperatively after extubation, especially 
after cardiac surgery. Sedation may conceal significant pain, because patients are unable to 
express pain verbally or otherwise early after extubation. This fact may worsen the 
precision of the measurement of pain scores early after surgery, and might diminish the 
differentiation between groups. However, heavy sedation after extubation was rare in 
studies II, III, and IV. Therefore, it appears unlikely that sedation significantly affected the 
results in these three studies.  
6.5 FUTURE PERSPECTIVES 
Currently, postoperative pain management after cardiac surgery is based on i.v. opioids in 
the PACU/ICU followed by i.m. or orally administered opioids on the surgical ward. 
However, dynamic pain is particularly difficult to alleviate with opioids. New approaches 
in pain therapy have not offered many improvements for postoperative pain management 
after cardiac surgery. NSAIDs are usually avoided for fear of renal adverse effects or 
bleeding complications, newer COX-2 inhibitors should be omitted because they are 
associated with an increased risk of thromboembolic complications and epidural catheters 
may cause bleeding and permanent paraplegia when systemic heparinization is employed. 
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At the moment, opioid-based pain control after cardiac surgery is clearly suboptimal 
based on this questionnaire study and previous investigations. The intense pain reported 
by cardiac surgery patients in the immediate postoperative period warrants additional 
studies to find more efficient opioid adjuncts or other methods to alleviate postoperative 
pain safely in cardiac surgery.  
Whether remifentanil induces opioid tolerance after cardiac surgery should be 
investigated in a future study in which higher and lower doses of remifentanil are 
administered to patients during surgery. Alternatively, total intravenous anesthesia based 
on propofol compared with inhalation anesthesia using sevoflurane or desflurane may 
reduce postoperative pain and should be evaluated in the context of cardiac surgery.  
Other ways to alleviate postoperative pain after cardiac surgery may include 
multimodal analgesia with combined pregabalin (Pesonen et al. 2011), preoperative 
dexamethasone administration, and the use of ketamine as a rescue bolus for opioid-
tolerant patients. If the results of a large (>4000 patients), ongoing study of dexamethasone 
indicate that its administration is safe in cardiac surgery, it could be a useful adjunct to 
analgesia in this patient group, because it appears to alleviate pain and decrease 
postoperative requirements in a recent large meta-analysis (cardiac surgery studies not 
included) (de Oliveira GS et al. 2011). Additionally, a low dose of intrathecal morphine 
combined with remifentanil analgesia during surgery and early extubation appears to be an 
effective way to treat postoperative pain (Zarate et al 2000). Hopefully, in the future we will 
be able to predict which patients will postoperatively require additional care for analgesia 
better than we can at present. Current quantitive sensory testing has been able to predict 
only 54% of the variance between individual patients (Werner et al 2010). It would also be 
helpful to be able to predict preoperatively when opioid tolerance or opioid-induced 
hyperalgesia should be considered, and perhaps treated with emerging possibilities (Wang 
et al. 2012 and Liang et al. 2011).  
In summary, pain after cardiac surgery is intense owing to stress response and tissue 
trauma that exceeds that of most other types of surgery. Therefore, different approaches 
and therapies are needed compared with other operations. Thus far, only suboptimal 
treatment modalities (mainly based on i.m. or i.v. opioids) are employed. Intensive acute 
postoperative pain is harmful and may predispose to persistent pain after cardiac surgery; 
hence, new treatment options should be scrutinized. Until new approaches have shown 
promise, post-extubation opioid titration to less-intense pain levels (i.e., VAS ≤ 3) during 
the immediate postoperative period appears warranted.  
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7 Conclusions 
1) Acute postoperative pain at worst was severe in 49% at rest, in 78% during coughing, 
and on movement in 62% of patients after CABG. Postoperative pain was more 
severe than patients expected preoperatively. 
 
2) Persistent post-sternotomy pain is common (although seldom severe) up to 1 year 
after surgery. In the present study, 17% of patients reported pain at rest and 31% 
reported pain on movement 1 year after CABG surgery. However, only 2% and 4% 
of patients had severe pain at rest and on movement, respectively, 1 year after 
surgery. 
 
3) Propacetamol did not reduce opioid requirement, nor did it enhance analgesia or 
reduce adverse effects within 3 days after cardiac surgery. 
 
4) S(+)-ketamine has an opioid-sparing effect (17% in the present trial); however, it may 
also induce untoward adverse effects, such as hallucinations and confusion, after 
cardiac surgery. 
 
5) High dose remifentanil infusion does not increase postoperative pain or opioid 
consumption after CABG surgery. In the present study, no opioid tolerance was 
detected after surgery. 
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Postoperative pain is inadequately 
treated and potential origin of 
persisting pain. The present study 
investigated acute and persisting 
pain after CABG surgery as well as 
propacetamol and S(+)-ketamine in 
pain therapy. Remifentanil´s effect on 
postoperative pain was also explored. 
Postoperative pain was moderate 
at rest, whereas dynamic pain was 
severe after surgery. One year after 
the operation persisting pain was 
common, although seldom severe. 
The efficacy of propacetamol and S(+)-
ketamine as analgesics after surgery 
was weak. Remifentanil did not 
increase pain postoperatively.
 
